DrugDDI.d201
DrugDDI.d201.s5
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4 , and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.

Drugs/NNS that/WDT Inhibit/VBP or/CC Induce/VBP Cytochrome/NN P450/NN 3A4/NN Enzymes/NNS Lapatinib/NN undergoes/VBZ extensive/JJ metabolism/NN by/IN CYP3A4/NN ,/, and/CC concomitant/JJ administration/NN of/IN strong/JJ inhibitors/NNS or/CC inducers/NNS of/IN CYP3A4/NN alter/VB lapatinib/NN concentrations/NNS significantly/RB ./.


DrugDDI.d201
DrugDDI.d201.s6
Dose adjustment of lapatinib should be considered for patients who must receive concomitant strong inhibitors or concomitant strong inducers of CYP3A4 enzymes.

Dose/NN adjustment/NN of/IN lapatinib/NN should/MD be/VB considered/VBN for/IN patients/NNS who/WP must/MD receive/VBP concomitant/JJ strong/JJ inhibitors/NNS or/CC concomitant/JJ strong/JJ inducers/NNS of/IN CYP3A4/JJ enzymes/NNS ./.


DrugDDI.d201
DrugDDI.d201.s7
Ketoconazole : In healthy subjects receiving ketoconazole , a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.

Ketoconazole/NN :/: In/IN healthy/JJ subjects/NNS receiving/VBG ketoconazole/NN ,/, a/DT CYP3A4/NN inhibitor/NN ,/, at/IN 200/CD mg/NN twice/RB daily/RB for/IN 7/CD days/NNS ,/, systemic/JJ exposure/NN (/-LRB- AUC/NN )/-RRB- to/TO lapatinib/NN was/VBD increased/VBN to/TO approximately/RB 3.6-fold/NN of/IN control/NN and/CC half-life/NN increased/VBD to/TO 1.7-fold/NN of/IN control/NN ./.


DrugDDI.d201
DrugDDI.d201.s8
Carbamazepine : In healthy subjects receiving the CYP3A4 inducer, carbamazepine , at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.

Carbamazepine/NN :/: In/IN healthy/JJ subjects/NNS receiving/VBG the/DT CYP3A4/NN inducer/NN ,/, carbamazepine/NN ,/, at/IN 100/CD mg/NN twice/RB daily/JJ for/IN 3/CD days/NNS and/CC 200/CD mg/NN twice/RB daily/JJ for/IN 17/CD days/NNS ,/, systemic/JJ exposure/NN (/-LRB- AUC/NN )/-RRB- to/TO lapatinib/NN was/VBD decreased/VBN approximately/RB 72/CD %./NN


DrugDDI.d201
DrugDDI.d201.s9
Drugs that Inhibit Drug Transport Systems Lapatinib is a substrate of the efflux transporter P-glycoprotein (Pgp, ABCB1 ).

Drugs/NNS that/WDT Inhibit/VBP Drug/NN Transport/NN Systems/NNS Lapatinib/NN is/VBZ a/DT substrate/NN of/IN the/DT efflux/NN transporter/NN P-glycoprotein/NN (/-LRB- Pgp/NN ,/, ABCB1/NN )/-RRB- ./.


DrugDDI.d201
DrugDDI.d201.s10
If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.

If/IN TYKERB/NN is/VBZ administered/VBN with/IN drugs/NNS that/WDT inhibit/VBP Pgp/NN ,/, increased/VBN concentrations/NNS of/IN lapatinib/NN are/VBP likely/JJ ,/, and/CC caution/NN should/MD be/VB exercised/VBN ./.


DrugDDI.d201
DrugDDI.d201.s11
Other Chemotherapy Agents : In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine ).

Other/JJ Chemotherapy/NN Agents/NNS :/: In/IN a/DT separate/JJ study/NN ,/, concomitant/JJ administration/NN of/IN lapatinib/NN with/IN capecitabine/NN did/VBD not/RB meaningfully/RB alter/VB the/DT pharmacokinetics/NNS of/IN either/DT agent/NN (/-LRB- or/CC the/DT metabolites/NNS of/IN capecitabine/NN )/-RRB- ./.


DrugDDI.d581
DrugDDI.d581.s0
Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide ) concentration .

Cholestyramine/NN and/CC Charcoal/NN Administration/NN of/IN cholestyramine/NN or/CC activated/VBN charcoal/NN in/IN patients/NNS (/-LRB- n=13/NN )/-RRB- and/CC volunteers/NNS (/-LRB- n=96/CD )/-RRB- resulted/VBD in/IN a/DT rapid/JJ and/CC significant/JJ decrease/NN in/IN plasma/NN M1/NN (/-LRB- the/DT active/JJ metabolite/NN of/IN leflunomide/NN )/-RRB- concentration/NN ./.


DrugDDI.d581
DrugDDI.d581.s1
Hepatotoxic Drugs Increased side effects may occur when leflunomide is given concomitantly with hepatotoxic substances.

Hepatotoxic/JJ Drugs/NNS Increased/VBN side/NN effects/NNS may/MD occur/VB when/WRB leflunomide/NN is/VBZ given/VBN concomitantly/RB with/IN hepatotoxic/JJ substances/NNS ./.


DrugDDI.d581
DrugDDI.d581.s2
This is also to be considered when leflunomide treatment is followed by such drugs without a drug elimination procedure.

This/DT is/VBZ also/RB to/TO be/VB considered/VBN when/WRB leflunomide/NN treatment/NN is/VBZ followed/VBN by/IN such/JJ drugs/NNS without/IN a/DT drug/NN elimination/NN procedure/NN ./.


DrugDDI.d581
DrugDDI.d581.s3
In a small (n=30) combination study of ARAVA with methotrexate , a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.

In/IN a/DT small/JJ (/-LRB- n=30/NN )/-RRB- combination/NN study/NN of/IN ARAVA/NN with/IN methotrexate/NN ,/, a/DT 2-/CD to/TO 3-fold/JJ elevation/NN in/IN liver/NN enzymes/NNS was/VBD seen/VBN in/IN 5/CD of/IN 30/CD patients/NNS ./.


DrugDDI.d581
DrugDDI.d581.s4
All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide .

All/DT elevations/NNS resolved/VBN ,/, 2/CD with/IN continuation/NN of/IN both/DT drugs/NNS and/CC 3/CD after/IN discontinuation/NN of/IN leflunomide/NN ./.


DrugDDI.d581
DrugDDI.d581.s6
All of these also resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide .

All/DT of/IN these/DT also/RB resolved/VBN ,/, 2/CD with/IN continuation/NN of/IN both/DT drugs/NNS and/CC 3/CD after/IN discontinuation/NN of/IN leflunomide/NN ./.


DrugDDI.d581
DrugDDI.d581.s7
Three patients met ACR criteria for liver biopsy (1: Roegnik Grade I, 2: Roegnik Grade IIIa).

Three/CD patients/NNS met/NN ACR/NN criteria/NNS for/IN liver/NN biopsy/NN (/-LRB- 1/CD :/: Roegnik/NNP Grade/NN I/CD ,/, 2/CD :/: Roegnik/NNP Grade/NN IIIa/NN )./NN


DrugDDI.d581
DrugDDI.d581.s9
NSAIDs : In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.

NSAIDs/NNS :/: In/IN in/FW vitro/FW studies/NNS ,/, M1/NN was/VBD shown/VBN to/TO cause/VB increases/NNS ranging/VBG from/IN 13/CD -/CC 50/CD %/NN in/IN the/DT free/JJ fraction/NN of/IN diclofenac/NN and/CC ibuprofen/NN at/IN concentrations/NNS in/IN the/DT clinical/JJ range/NN ./.


DrugDDI.d581
DrugDDI.d581.s11
however, there was extensive concomitant use of NSAIDs in clinical studies and no differential effect was observed.

however/RB ,/, there/EX was/VBD extensive/JJ concomitant/JJ use/NN of/IN NSAIDs/NN in/IN clinical/JJ studies/NNS and/CC no/DT differential/JJ effect/NN was/VBD observed/VBN ./.


DrugDDI.d581
DrugDDI.d581.s12
Tolbutamide : In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range.

Tolbutamide/NN :/: In/IN in/FW vitro/FW studies/NNS ,/, M1/NN was/VBD shown/VBN to/TO cause/VB increases/NNS ranging/VBG from/IN 13/CD -/CC 50/CD %/NN in/IN the/DT free/JJ fraction/NN of/IN tolbutamide/NN at/IN concentrations/NNS in/IN the/DT clinical/JJ range/NN ./.


DrugDDI.d581
DrugDDI.d581.s14
Rifampin Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin , M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.

Rifampin/NN Following/VBG concomitant/JJ administration/NN of/IN a/DT single/JJ dose/NN of/IN ARAVA/NN to/TO subjects/NNS receiving/VBG multiple/JJ doses/NNS of/IN rifampin/NN ,/, M1/NN peak/NN levels/NNS were/VBD increased/VBN (/-LRB- ~40/CD %/NN )/-RRB- over/IN those/DT seen/VBN when/WRB ARAVA/NN was/VBD given/VBN alone/RB ./.


DrugDDI.d581
DrugDDI.d581.s15
Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin .

Because/IN of/IN the/DT potential/NN for/IN ARAVA/NN levels/NNS to/TO continue/VBP to/TO increase/VB with/IN multiple/JJ dosing/NN ,/, caution/NN should/MD be/VB used/VBN if/IN patients/NNS are/VBP to/TO be/VB receiving/VBG both/CC ARAVA/NN and/CC rifampin/NN ./.


DrugDDI.d581
DrugDDI.d581.s16
Warfarin Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.

Warfarin/JJ Increased/VBN INR/NN (/-LRB- International/NNP Normalized/VBN Ratio/NN )/-RRB- when/WRB ARAVA/NN and/CC warfarin/NN were/VBD co-administered/VBN has/VBZ been/VBN rarely/RB reported/VBN ./.


DrugDDI.d379
DrugDDI.d379.s0
Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.

Clinical/JJ interaction/NN studies/NNS with/IN cimetidine/NN and/CC warfarin/NN indicated/VBD that/IN the/DT coadministration/NN of/IN Femara/NN with/IN these/DT drugs/NNS does/VBZ not/RB result/VB in/IN clinically-/JJ significant/JJ drug/NN interactions/NNS ./.


DrugDDI.d379
DrugDDI.d379.s1
(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.

(/-LRB- See/VB CLINICAL/JJ PHARMACOLOGY/NN )/-RRB- Coadministration/NN of/IN Femara/NN and/CC tamoxifen/NN 20/CD mg/NN daily/RB resulted/VBD in/IN a/DT reduction/NN of/IN letrozole/NN plasma/NN levels/NNS by/IN 38/CD %/NN on/IN average/NN ./.


DrugDDI.d379
DrugDDI.d379.s2
There is no clinical experience to date on the use of Femara in combination with other anticancer agents.

There/EX is/VBZ no/DT clinical/JJ experience/VBP to/TO date/VB on/IN the/DT use/NN of/IN Femara/NN in/IN combination/NN with/IN other/JJ anticancer/JJ agents/NNS ./.


DrugDDI.d379
DrugDDI.d379.s3
Drug /Laboratory Test-Interactions None observed.

Drug/NN /Laboratory/NN Test-Interactions/NN None/NN observed/VBN ./.


DrugDDI.d341
DrugDDI.d341.s0
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital , phenytoin and primidone , and increase the frequency of seizures in susceptible pediatric patients.

Folic/JJ acid/NN in/IN large/JJ amounts/NNS may/MD counteract/VB the/DT antiepileptic/JJ effect/NN of/IN phenobarbital/NN ,/, phenytoin/NN and/CC primidone/NN ,/, and/CC increase/VB the/DT frequency/NN of/IN seizures/NNS in/IN susceptible/JJ pediatric/JJ patients/NNS ./.


DrugDDI.d341
DrugDDI.d341.s1
Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.

Preliminary/JJ animal/JJ and/CC human/JJ studies/NNS have/VBP shown/VBN that/IN small/JJ quantities/NNS of/IN systemically/RB administered/VBN leucovorin/NN enter/VBP the/DT CSF/NN primarily/RB as/IN 5-methyltetrahydro-folate/NN and/CC ,/, in/IN humans/NNS ,/, remain/VBP 1/CD to/TO 3/CD orders/NNS of/IN magnitude/NN lower/JJR than/IN the/DT usual/JJ methotrexate/NN concentrations/NNS following/VBG intrathecal/JJ administration/NN ./.


DrugDDI.d341
DrugDDI.d341.s2
However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate .

However/RB ,/, high/JJ doses/NNS of/IN leucovorin/NN may/MD reduce/VB the/DT efficacy/NN of/IN intrathecally/RB administered/VBN methotrexate/NN ./.


DrugDDI.d341
DrugDDI.d341.s3
Leucovorin may enhance the toxicity of 5- fluorouracil .

Leucovorin/NN may/MD enhance/VB the/DT toxicity/NN of/IN 5-/CD fluorouracil/NN ./.


DrugDDI.d484
DrugDDI.d484.s0
Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.

Although/IN BETAGAN/NN used/VBN alone/RB has/VBZ little/JJ or/CC no/DT effect/NN on/IN pupil/NN size/NN ,/, mydriasis/NNS resulting/VBG from/IN concomitant/JJ therapy/NN with/IN BETAGAN/NN and/CC epinephrine/NN may/MD occur/VB ./.


DrugDDI.d484
DrugDDI.d484.s1
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine , because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.

Close/JJ observation/NN of/IN the/DT patient/NN is/VBZ recommended/VBN when/WRB a/DT beta-blocker/NN is/VBZ administered/VBN to/TO patients/NNS receiving/VBG catecholamine-depleting/JJ drugs/NNS such/JJ as/IN reserpine/NN ,/, because/IN of/IN possible/JJ additive/JJ effects/NNS and/CC the/DT production/NN of/IN hypotension/NN and/or/CC marked/JJ bradycardia/NN ,/, which/WDT may/MD produce/VB vertigo/NN ,/, syncope/NN or/CC postural/JJ hypotension/NN ./.


DrugDDI.d484
DrugDDI.d484.s2
Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonist s should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.

Patients/NNS receiving/VBG beta-adrenergic/JJ blocking/NN agents/NNS along/IN with/IN either/CC oral/JJ or/CC intravenous/JJ calcium/NN antagonist/NN s/NN should/MD be/VB monitored/VBN for/IN possible/JJ atrioventricular/JJ conduction/NN disturbances/NNS ,/, left/JJ ventricular/NN failure/NN and/CC hypotension/NN ./.


DrugDDI.d484
DrugDDI.d484.s4
The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonist s may have additive effects on prolonging atrioventricular conduction time.

The/DT concomitant/JJ use/NN of/IN beta-adrenergic/JJ blocking/NN agents/NNS with/IN digitalis/NN and/CC calcium/NN antagonist/NN s/NN may/MD have/VB additive/JJ effects/NNS on/IN prolonging/VBG atrioventricular/JJ conduction/NN time/NN ./.


DrugDDI.d484
DrugDDI.d484.s5
Phenothiazine -related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other@s metabolism.

Phenothiazine/JJ -related/JJ compounds/NNS and/CC beta-adrenergic/JJ blocking/NN agents/NNS may/MD have/VB additive/JJ hypotensite/JJ effects/NNS due/JJ to/TO the/DT inhibition/NN of/IN each/DT other/JJ @/NN s/NN metabolism/NN ./.


DrugDDI.d112
DrugDDI.d112.s0
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide , digoxin , warfarin , cimetidine and phenobarbital .

No/DT significant/JJ drug-drug/JJ pharmacokinetic/JJ interactions/NNS have/VBP been/VBN found/VBN in/IN interaction/NN studies/NNS with/IN hydrochlorothiazide/NN ,/, digoxin/NN ,/, warfarin/NN ,/, cimetidine/NN and/CC phenobarbital/NN ./.


DrugDDI.d112
DrugDDI.d112.s1
Rifampin , an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite .

Rifampin/NN ,/, an/DT inducer/NN of/IN drug/NN metabolism/NN ,/, decreased/VBD the/DT concentrations/NNS of/IN losartan/NN and/CC its/PRP$ active/JJ metabolite/NN ./.


DrugDDI.d112
DrugDDI.d112.s2
In humans, two inhibitors of P450 3A4 have been studied.

In/IN humans/NNS ,/, two/CD inhibitors/NNS of/IN P450/NN 3A4/NN have/VBP been/VBN studied/VBN ./.


DrugDDI.d112
DrugDDI.d112.s3
Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan , and erythromycin had no clinically significant effect after oral administration.

Ketoconazole/NN did/VBD not/RB affect/VB the/DT conversion/NN of/IN losartan/NN to/TO the/DT active/JJ metabolite/NN after/IN intravenous/JJ administration/NN of/IN losartan/NN ,/, and/CC erythromycin/NN had/VBD no/DT clinically/RB significant/JJ effect/NN after/IN oral/JJ administration/NN ./.


DrugDDI.d112
DrugDDI.d112.s4
Fluconazole , an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.

Fluconazole/NN ,/, an/DT inhibitor/NN of/IN P450/NN 2C9/NNS ,/, decreased/VBD active/JJ metabolite/NN concentration/NN and/CC increased/VBD losartan/NN concentration/NN ./.


DrugDDI.d112
DrugDDI.d112.s5
The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined.

The/DT pharmacodynamic/JJ consequences/NNS of/IN concomitant/JJ use/NN of/IN losartan/NN and/CC inhibitors/NNS of/IN P450/NN 2C9/NNS have/VBP not/RB been/VBN examined/VBN ./.


DrugDDI.d112
DrugDDI.d112.s6
Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9 .

Subjects/NNS who/WP do/VBP not/RB metabolize/VB losartan/NN to/TO active/JJ metabolite/NN have/VBP been/VBN shown/VBN to/TO have/VB a/DT specific/JJ ,/, rare/JJ defect/NN in/IN cytochrome/NN P450/NN 2C9/NN ./.


DrugDDI.d112
DrugDDI.d112.s7
These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4 .

These/DT data/NNS suggest/VBP that/IN the/DT conversion/NN of/IN losartan/NN to/TO its/PRP$ active/JJ metabolite/NN is/VBZ mediated/VBN primarily/RB by/IN P450/NN 2C9/NN and/CC not/RB P450/NN 3A4/NN ./.


DrugDDI.d112
DrugDDI.d112.s8
As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone , triamterene , amiloride ), potassium supplement s, or salt substitutes containing potassium may lead to increases in serum potassium.

As/IN with/IN other/JJ drugs/NNS that/WDT block/VBP angiotensin/NN II/CD or/CC its/PRP$ effects/NNS ,/, concomitant/JJ use/NN of/IN potassium-sparing/JJ diuretics/NNS (/-LRB- e.g./FW ,/, spironolactone/NN ,/, triamterene/NN ,/, amiloride/NN )/-RRB- ,/, potassium/NN supplement/NN s/NNS ,/, or/CC salt/NN substitutes/VBZ containing/VBG potassium/NN may/MD lead/VB to/TO increases/NNS in/IN serum/NN potassium/NN ./.


DrugDDI.d112
DrugDDI.d112.s9
As with other antihypertensive agents , the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin .

As/IN with/IN other/JJ antihypertensive/JJ agents/NNS ,/, the/DT antihypertensive/JJ effect/NN of/IN losartan/NN may/MD be/VB blunted/VBN by/IN the/DT non-steroidal/JJ anti-inflammatory/JJ drug/NN indomethacin/NN ./.


DrugDDI.d464
DrugDDI.d464.s0
When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents : Anesthetics , general: exaggeration of the hypotension induced by general anesthetics .

When/WRB administered/VBN concurrently/RB ,/, the/DT following/VBG drugs/NNS may/MD interact/VB with/IN beta-adrenergic/JJ receptor/NN blocking/NN agents/NNS :/: Anesthetics/NN ,/, general/JJ :/: exaggeration/NN of/IN the/DT hypotension/NN induced/VBN by/IN general/JJ anesthetics/NNS ./.


DrugDDI.d464
DrugDDI.d464.s1
Antidiabetic drugs (oral agents and insulin ): hypoglycemia or hyperglycemia; .

Antidiabetic/JJ drugs/NNS (/-LRB- oral/JJ agents/NNS and/CC insulin/NN )/-RRB- :/: hypoglycemia/NN or/CC hyperglycemia/NN ;/: ./.


DrugDDI.d464
DrugDDI.d464.s2
adjust dosage of antidiabetic drug accordingly.

adjust/VB dosage/NN of/IN antidiabetic/JJ drug/NN accordingly/RB ./.


DrugDDI.d464
DrugDDI.d464.s3
Catecholamine-depleting drugs (e.g., reserpine ): additive effect; .

Catecholamine-depleting/JJ drugs/NNS (/-LRB- e.g./FW ,/, reserpine/NN )/-RRB- :/: additive/JJ effect/NN ;/: ./.


DrugDDI.d464
DrugDDI.d464.s5
Response to Treatment for Anaphylactic Reaction: While taking beta-blockers , patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.

Response/NN to/TO Treatment/NN for/IN Anaphylactic/JJ Reaction/NN :/: While/IN taking/VBG beta-blockers/NN ,/, patients/NNS with/IN a/DT history/NN of/IN severe/JJ anaphylactic/JJ reaction/NN to/TO a/DT variety/NN of/IN allergens/NNS may/MD be/VB more/RBR reactive/JJ to/TO repeated/JJ challenge/NN ,/, either/CC accidental/JJ ,/, diagnostic/JJ ,/, or/CC therapeutic/JJ ./.


DrugDDI.d464
DrugDDI.d464.s6
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

Such/JJ patients/NNS may/MD be/VB unresponsive/JJ to/TO the/DT usual/JJ doses/NNS of/IN epinephrine/NN used/VBN to/TO treat/VB allergic/JJ reaction/NN ./.


DrugDDI.d485
DrugDDI.d485.s0
Elevated plasma levels of theophylline have been reported with concomitant quinolone use.

Elevated/JJ plasma/NN levels/NNS of/IN theophylline/NN have/VBP been/VBN reported/VBN with/IN concomitant/JJ quinolone/NN use/NN ./.


DrugDDI.d485
DrugDDI.d485.s1
There have been reports of theophylline -related side effects in patients on concomitant therapy with quinolones and theophylline .

There/EX have/VBP been/VBN reports/NNS of/IN theophylline/NN -related/JJ side/JJ effects/NNS in/IN patients/NNS on/IN concomitant/JJ therapy/NN with/IN quinolones/NNS and/CC theophylline/NN ./.


DrugDDI.d485
DrugDDI.d485.s2
Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.

Therefore/RB ,/, monitoring/NN of/IN theophylline/NN plasma/NN levels/NNS should/MD be/VB considered/VBN and/CC dosage/NN of/IN theophylline/NN adjusted/VBN ,/, as/IN required/VBN ./.


DrugDDI.d485
DrugDDI.d485.s3
Quinolones have been shown to interfere with the metabolism of caffeine .

Quinolones/NNS have/VBP been/VBN shown/VBN to/TO interfere/VB with/IN the/DT metabolism/NN of/IN caffeine/NN ./.


DrugDDI.d485
DrugDDI.d485.s4
This may lead to reduced clearance of caffeine and the prolongation of its plasma half-life.

This/DT may/MD lead/VB to/TO reduced/VBN clearance/NN of/IN caffeine/NN and/CC the/DT prolongation/NN of/IN its/PRP$ plasma/NN half-life/NN ./.


DrugDDI.d485
DrugDDI.d485.s5
Quinolones , including nalidixic acid , may enhance the effects of the oral anticoagulant warfarin or its derivatives .

Quinolones/NNS ,/, including/VBG nalidixic/JJ acid/NN ,/, may/MD enhance/VB the/DT effects/NNS of/IN the/DT oral/JJ anticoagulant/NN warfarin/NN or/CC its/PRP$ derivatives/NNS ./.


DrugDDI.d485
DrugDDI.d485.s7
Nitrofurantoin interferes with the therapeutic action of nalidixic acid .

Nitrofurantoin/NN interferes/VBZ with/IN the/DT therapeutic/JJ action/NN of/IN nalidixic/JJ acid/NN ./.


DrugDDI.d485
DrugDDI.d485.s8
Antacids containing magnesium , aluminum, or calcium ; .

Antacids/NNS containing/VBG magnesium/NN ,/, aluminum/NN ,/, or/CC calcium/NN ;/: ./.


DrugDDI.d485
DrugDDI.d485.s9
sucralfate or divalent or trivalent cations such as iron ; .

sucralfate/VBP or/CC divalent/JJ or/CC trivalent/JJ cations/NNS such/JJ as/IN iron/NN ;/: ./.


DrugDDI.d485
DrugDDI.d485.s10
multivitamins containing zinc ; .

multivitamins/NNS containing/VBG zinc/NN ;/: ./.


DrugDDI.d485
DrugDDI.d485.s11
and Videx@, ( Didanosine ), chewable/ buffer ed tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones , resulting in systemic levels considerably lower than desired.

and/CC Videx/NN @/NN ,/, (/-LRB- Didanosine/NN )/-RRB- ,/, chewable//NN buffer/NN ed/NN tablets/NNS or/CC the/DT pediatric/JJ powder/NN for/IN oral/JJ solution/NN may/MD substantially/RB interfere/VB with/IN the/DT absorption/NN of/IN quinolones/NNS ,/, resulting/VBG in/IN systemic/JJ levels/NNS considerably/RB lower/JJR than/IN desired/VBN ./.


DrugDDI.d485
DrugDDI.d485.s12
These agents should not be taken within the two hour period before or within the two-hour period after nalidixic acid administration.

These/DT agents/NNS should/MD not/RB be/VB taken/VBN within/IN the/DT two/CD hour/NN period/NN before/IN or/CC within/IN the/DT two-hour/JJ period/NN after/IN nalidixic/JJ acid/NN administration/NN ./.


DrugDDI.d485
DrugDDI.d485.s13
Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine .

Elevated/JJ serum/NN levels/NNS of/IN cyclosporine/NN have/VBP been/VBN reported/VBN with/IN the/DT concomitant/JJ use/NN of/IN some/DT quinolones/NN and/CC cyclosporine/NN ./.


DrugDDI.d485
DrugDDI.d485.s14
Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.

Therefore/RB ,/, cyclosporine/NN serum/NN levels/NNS should/MD be/VB monitored/VBN and/CC appropriate/JJ cyclosporine/NN dosage/NN adjustments/NNS made/VBD when/WRB these/DT drugs/NNS are/VBP used/VBN concomitantly/RB ./.


DrugDDI.d249
DrugDDI.d249.s0
In vitro drug metabolism studies indicate that Starlix is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%).

In/FW vitro/FW drug/NN metabolism/NN studies/NNS indicate/VBP that/IN Starlix/NN is/VBZ predominantly/RB metabolized/VBN by/IN the/DT cytochrome/NN P450/NN isozyme/NN CYP2C9/NN (/-LRB- 70/CD %/NN )/-RRB- and/CC to/TO a/DT lesser/JJR extent/NN CYP3A4/NN (/-LRB- 30%)./NN


DrugDDI.d249
DrugDDI.d249.s1
Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide .

Starlix/NN is/VBZ a/DT potential/JJ inhibitor/NN of/IN the/DT CYP2C9/NN isoenzyme/NN in/FW vivo/FW as/IN indicated/VBN by/IN its/PRP$ ability/NN to/TO inhibit/VB the/DT in/FW vitro/FW metabolism/NN of/IN tolbutamide/NN ./.


DrugDDI.d249
DrugDDI.d249.s2
Inhibition of CYP3A4 metabolic reactions was not detected in in vitro experiments.

Inhibition/NN of/IN CYP3A4/JJ metabolic/JJ reactions/NNS was/VBD not/RB detected/VBN in/IN in/FW vitro/FW experiments/NNS ./.


DrugDDI.d249
DrugDDI.d249.s3
Glyburide : In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.

Glyburide/NN :/: In/IN a/DT randomized/JJ ,/, multiple-dose/JJ crossover/NN study/NN ,/, patients/NNS with/IN Type/NN 2/CD diabetes/NNS were/VBD administered/VBN 120/CD mg/NN Starlix/NN three/CD times/NNS a/DT day/NN before/IN meals/NN for/IN 1/CD day/NN in/IN combination/NN with/IN glyburide/NN 10/CD mg/NN daily/RB ./.


DrugDDI.d249
DrugDDI.d249.s5
Metformin : When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.

Metformin/NN :/: When/WRB Starlix/NN 120/CD mg/NN three/CD times/NNS daily/RB before/IN meals/NN was/VBD administered/VBN in/IN combination/NN with/IN metformin/NN 500/CD mg/NN three/CD times/NNS daily/JJ to/TO patients/NNS with/IN Type/NN 2/CD diabetes/NNS ,/, there/EX were/VBD no/DT clinically/RB relevant/JJ changes/NNS in/IN the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.


DrugDDI.d249
DrugDDI.d249.s6
Digoxin : When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.

Digoxin/NN :/: When/WRB Starlix/NN 120/CD mg/NN before/IN meals/NN was/VBD administered/VBN in/IN combination/NN with/IN a/DT single/JJ 1-mg/JJ dose/NN of/IN digoxin/NN to/TO healthy/JJ volunteers/NNS ,/, there/EX were/VBD no/DT clinically/RB relevant/JJ changes/NNS in/IN the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.


DrugDDI.d249
DrugDDI.d249.s7
Warfarin : When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.

Warfarin/NN :/: When/WRB healthy/JJ subjects/NNS were/VBD administered/VBN Starlix/NN 120/CD mg/NN three/CD times/NNS daily/RB before/IN meals/NN for/IN four/CD days/NNS in/IN combination/NN with/IN a/DT single/JJ dose/NN of/IN warfarin/NN 30/CD mg/NN on/IN day/NN 2/CD ,/, there/EX were/VBD no/DT alterations/NNS in/IN the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.


DrugDDI.d249
DrugDDI.d249.s9
Diclofenac : Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.

Diclofenac/NN :/: Administration/NN of/IN morning/NN and/CC lunch/NN doses/NNS of/IN Starlix/NN 120/CD mg/NN in/IN combination/NN with/IN a/DT single/JJ 75-mg/NN dose/NN of/IN diclofenac/NN in/IN healthy/JJ volunteers/NNS resulted/VBD in/IN no/DT significant/JJ changes/NNS to/TO the/DT pharmacokinetics/NNS of/IN either/DT agent/NN ./.


DrugDDI.d249
DrugDDI.d249.s10
Nateglinide is highly bound to plasma proteins (98%), mainly albumin .

Nateglinide/NN is/VBZ highly/RB bound/VBN to/TO plasma/NN proteins/NNS (/-LRB- 98/CD %/NN )/-RRB- ,/, mainly/RB albumin/NN ./.


DrugDDI.d249
DrugDDI.d249.s11
In vitro displacement studies with highly protein -bound drugs such as furosemide , propranolol , captopril , nicardipine , pravastatin , glyburide , warfarin , phenytoin , acetylsalicylic acid , tolbutamide , and metformin showed no influence on the extent of nateglinide protein binding.

In/FW vitro/FW displacement/NN studies/NNS with/IN highly/RB protein/NN -bound/JJ drugs/NNS such/JJ as/IN furosemide/NN ,/, propranolol/NN ,/, captopril/NN ,/, nicardipine/NN ,/, pravastatin/NN ,/, glyburide/NN ,/, warfarin/NN ,/, phenytoin/NN ,/, acetylsalicylic/JJ acid/NN ,/, tolbutamide/NN ,/, and/CC metformin/NN showed/VBD no/DT influence/NN on/IN the/DT extent/NN of/IN nateglinide/JJ protein/NN binding/NN ./.


DrugDDI.d249
DrugDDI.d249.s12
Similarly, nateglinide had no influence on the serum protein binding of propranolol , glyburide , nicardipine , warfarin , phenytoin , acetylsalicylic acid , and tolbutamide in vitro .

Similarly/RB ,/, nateglinide/NN had/VBD no/DT influence/NN on/IN the/DT serum/NN protein/NN binding/NN of/IN propranolol/NN ,/, glyburide/NN ,/, nicardipine/NN ,/, warfarin/NN ,/, phenytoin/NN ,/, acetylsalicylic/JJ acid/NN ,/, and/CC tolbutamide/NN in/FW vitro/FW ./.


DrugDDI.d249
DrugDDI.d249.s14
Certain drugs , including nonsteroidal anti-inflammatory agents ( NSAIDs ), salicylates , monoamine oxidase inhibitors , and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs .

Certain/JJ drugs/NNS ,/, including/VBG nonsteroidal/JJ anti-inflammatory/JJ agents/NNS (/-LRB- NSAIDs/NNS )/-RRB- ,/, salicylates/NNS ,/, monoamine/NN oxidase/NN inhibitors/NNS ,/, and/CC non-selective/JJ beta-adrenergic-blocking/JJ agents/NNS may/MD potentiate/VB the/DT hypoglycemic/JJ action/NN of/IN Starlix/NN and/CC other/JJ oral/JJ antidiabetic/JJ drugs/NNS ./.


DrugDDI.d249
DrugDDI.d249.s15
Certain drugs including thiazides , corticosteroids , thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs .

Certain/JJ drugs/NNS including/VBG thiazides/NNS ,/, corticosteroids/NNS ,/, thyroid/NN products/NNS ,/, and/CC sympathomimetics/NNS may/MD reduce/VB the/DT hypoglycemic/JJ action/NN of/IN Starlix/NN and/CC other/JJ oral/JJ antidiabetic/JJ drugs/NNS ./.


DrugDDI.d249
DrugDDI.d249.s16
When these drugs are administered to or withdrawn from patients receiving Starlix , the patient should be observed closely for changes in glycemic control.

When/WRB these/DT drugs/NNS are/VBP administered/VBN to/TO or/CC withdrawn/VBN from/IN patients/NNS receiving/VBG Starlix/NN ,/, the/DT patient/NN should/MD be/VB observed/VBN closely/RB for/IN changes/NNS in/IN glycemic/JJ control/NN ./.


DrugDDI.d312
DrugDDI.d312.s0
In clinical studies, Tilade has been co-administered with other anti-asthma medications , including inhaled and oral bronchodilators , and inhaled corticosteroids , with no evidence of increased frequency of adverse events or laboratory abnormalities.

In/IN clinical/JJ studies/NNS ,/, Tilade/NN has/VBZ been/VBN co-administered/VBN with/IN other/JJ anti-asthma/NN medications/NNS ,/, including/VBG inhaled/JJ and/CC oral/JJ bronchodilators/NNS ,/, and/CC inhaled/JJ corticosteroids/NNS ,/, with/IN no/DT evidence/NN of/IN increased/VBN frequency/NN of/IN adverse/JJ events/NNS or/CC laboratory/NN abnormalities/NNS ./.


DrugDDI.d336
DrugDDI.d336.s0
Caution should be taken in concurrent or serial use of other neurotoxic and/ or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of neomycin .

Caution/NN should/MD be/VB taken/VBN in/IN concurrent/JJ or/CC serial/JJ use/NN of/IN other/JJ neurotoxic/JJ and//NN or/CC nephrotoxic/JJ drugs/NNS because/IN of/IN possible/JJ enhancement/NN of/IN the/DT nephrotoxicity/NN and/or/CC ototoxicity/NN of/IN neomycin/NN ./.


DrugDDI.d336
DrugDDI.d336.s1
Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin@s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate@s neuromuscular blocking effects.

Caution/NN should/MD also/RB be/VB taken/VBN in/IN concurrent/JJ or/CC serial/JJ use/NN of/IN other/JJ aminoglycosides/NNS and/CC polymyxins/NNS because/IN they/PRP may/MD enhance/VB neomycin/NN @/NN s/NN nephrotoxicity/NN and/or/CC ototoxicity/NN and/CC potentiate/VB neomycin/NN sulfate/NN @/NN s/NN neuromuscular/JJ blocking/VBG effects/NNS ./.


DrugDDI.d336
DrugDDI.d336.s2
Oral neomycin inhibits the gastrointestinal absorption of penicillin V , oral vitamin B-12 , methotrexate and 5-fluorouracil .

Oral/JJ neomycin/NN inhibits/VBZ the/DT gastrointestinal/JJ absorption/NN of/IN penicillin/NN V/NN ,/, oral/JJ vitamin/NN B-12/NN ,/, methotrexate/NN and/CC 5-fluorouracil/NN ./.


DrugDDI.d336
DrugDDI.d336.s3
The gastrointestinal absorption of digoxin also appears to be inhibited.

The/DT gastrointestinal/JJ absorption/NN of/IN digoxin/NN also/RB appears/VBZ to/TO be/VB inhibited/VBN ./.


DrugDDI.d336
DrugDDI.d336.s5
Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.

Oral/JJ neomycin/NN sulfate/NN may/MD enhance/VB the/DT effect/NN of/IN coumarin/NN in/IN anticoagulants/NNS by/IN decreasing/VBG vitamin/NN K/NN availability/NN ./.


DrugDDI.d266
DrugDDI.d266.s0
Beta-adrenergic Blocking Agents : Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agent s is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.

Beta-adrenergic/JJ Blocking/NN Agents/NNS :/: Experience/VBP in/IN over/IN 1400/CD patients/NNS in/IN a/DT non-comparative/JJ clinical/JJ trial/NN has/VBZ shown/VBN that/IN concomitant/JJ administration/NN of/IN nifedipine/NN and/CC beta-blocking/JJ agent/NN s/NNS is/VBZ usually/RB well/RB tolerated/VBN ,/, but/CC there/EX have/VBP been/VBN occasional/JJ literature/NN reports/NNS suggesting/VBG that/IN the/DT combination/NN may/MD increase/VBP the/DT likelihood/NN of/IN congestive/JJ heart/NN failure/NN ,/, severe/JJ hypotension/NN or/CC exacerbation/NN of/IN angina/NN ./.


DrugDDI.d266
DrugDDI.d266.s1
Long Acting Nitrates : Nifedipine may be safely co-administered with nitrates , but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.

Long/JJ Acting/NN Nitrates/NNS :/: Nifedipine/NN may/MD be/VB safely/RB co-administered/VBN with/IN nitrates/NNS ,/, but/CC there/EX have/VBP been/VBN no/DT controlled/JJ studies/NNS to/TO evaluate/VB the/DT antianginal/JJ effectiveness/NN of/IN this/DT combination/NN ./.


DrugDDI.d266
DrugDDI.d266.s2
Digitalis : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.

Digitalis/NN :/: Immediate/JJ Release/NN Capsules/NNS :/: Since/IN there/EX have/VBP been/VBN isolated/VBN reports/NNS of/IN patients/NNS with/IN elevated/JJ digoxin/NN levels/NNS ,/, and/CC there/EX is/VBZ a/DT possible/JJ interaction/NN between/IN digoxin/NN and/CC nifedipine/NN ,/, it/PRP is/VBZ recommended/VBN that/IN digoxin/NN levels/NNS be/VB monitored/VBN when/WRB initiating/VBG ,/, adjusting/VBG ,/, and/CC discontinuing/VBG nifedipine/NN to/TO avoid/VB possible/JJ over-/NN or/CC under-digitalization/NN ./.


DrugDDI.d266
DrugDDI.d266.s3
Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.

Extended/JJ Release/NN Tablets/NNS :/: Administration/NN of/IN nifedipine/NN with/IN digoxin/NN increased/VBD digoxin/NN levels/NNS in/IN 9/CD of/IN 12/CD normal/JJ volunteers/NNS ./.


DrugDDI.d266
DrugDDI.d266.s7
Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.

Since/IN there/EX have/VBP been/VBN isolated/VBN reports/NNS of/IN patients/NNS with/IN elevated/JJ digoxin/NN levels/NNS ,/, it/PRP is/VBZ recommended/VBN that/IN digoxin/NN levels/NNS be/VB monitored/VBN when/WRB initiating/VBG ,/, adjusting/VBG ,/, and/CC discontinuing/VBG nifedipine/NN to/TO avoid/VB possible/JJ over-/NN or/CC under-digitalization/NN ./.


DrugDDI.d266
DrugDDI.d266.s8
Quinidine : Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine ).

Quinidine/NN :/: Immediate/JJ Release/NN Capsules/NNS :/: There/EX have/VBP been/VBN rare/JJ reports/NNS of/IN an/DT interaction/NN between/IN quinidine/NN and/CC nifedipine/NN (/-LRB- with/IN a/DT decreased/VBN plasma/NN level/NN of/IN quinidine/NN )/-RRB- ./.


DrugDDI.d266
DrugDDI.d266.s9
Coumarin Anticoagulant s: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulant s to whom nifedipine was administered.

Coumarin/NN Anticoagulant/NN s/NNS :/: There/EX have/VBP been/VBN rare/JJ reports/NNS of/IN increased/VBN prothrombin/NN time/NN in/IN patients/NNS taking/VBG coumarin/NN anticoagulant/NN s/NNS to/TO whom/WP nifedipine/NN was/VBD administered/VBN ./.


DrugDDI.d266
DrugDDI.d266.s10
However, the relationship to nifedipine therapy is uncertain.

However/RB ,/, the/DT relationship/NN to/TO nifedipine/NN therapy/NN is/VBZ uncertain/JJ ./.


DrugDDI.d266
DrugDDI.d266.s11
Cimetidine : A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.

Cimetidine/NN :/: A/DT study/NN in/IN 6/CD healthy/JJ volunteers/NNS has/VBZ shown/VBN a/DT significant/JJ increase/NN in/IN peak/NN nifedipine/NN plasma/NN levels/NNS (/-LRB- 80/CD %/NN )/-RRB- and/CC area-under-the-curve/JJ (/-LRB- 74/CD %/NN )/-RRB- after/IN a/DT 1/CD week/NN course/NN of/IN cimetidine/NN at/IN 1000/CD mg/NN per/IN day/NN and/CC nifedipine/NN at/IN 40/CD mg/NN per/IN day/NN ./.


DrugDDI.d266
DrugDDI.d266.s12
Ranitidine produced smaller, non-significant increases.

Ranitidine/NN produced/VBD smaller/JJR ,/, non-significant/JJ increases/NNS ./.


DrugDDI.d266
DrugDDI.d266.s13
The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450 , the enzyme system probably responsible for the first-pass metabolism of nifedipine .

The/DT effect/NN may/MD be/VB mediated/VBN by/IN the/DT known/JJ inhibition/NN of/IN cimetidine/NN on/IN hepatic/JJ cytochrome/NN P-450/NN ,/, the/DT enzyme/NN system/NN probably/RB responsible/JJ for/IN the/DT first-pass/NN metabolism/NN of/IN nifedipine/NN ./.


DrugDDI.d266
DrugDDI.d266.s14
If nifedipine therapy is initiated in a patient currently receiving cimetidine , cautious titration is advised.

If/IN nifedipine/NN therapy/NN is/VBZ initiated/VBN in/IN a/DT patient/NN currently/RB receiving/VBG cimetidine/NN ,/, cautious/JJ titration/NN is/VBZ advised/VBN ./.


DrugDDI.d234
DrugDDI.d234.s0
A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.

A/DT 30/CD to/TO 45/CD %/NN increase/NN in/IN AUC/NN and/CC Cmax/NN of/IN nisoldipine/NN was/VBD observed/VBN with/IN concomitant/JJ administration/NN of/IN cimetidine/NN 400/CD mg/NN twice/RB daily/RB ./.


DrugDDI.d234
DrugDDI.d234.s1
Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).

Ranitidine/NN 150/CD mg/NN twice/RB daily/RB did/VBD not/RB interact/VB significantly/RB with/IN nisoldipine/NN (/-LRB- AUC/NN was/VBD decreased/VBN by/IN 15-20/CD %/NN )./CD


DrugDDI.d234
DrugDDI.d234.s2
No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.

No/DT pharmacodynamic/JJ effects/NNS of/IN either/DT histamine/NN H2/NN receptor/NN antagonist/NN were/VBD observed/VBN ./.


DrugDDI.d234
DrugDDI.d234.s3
Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.

Coadministration/NN of/IN phenytoin/NN with/IN 40/CD mg/NN SULAR/NN tablets/NNS in/IN epileptic/JJ patients/NNS lowered/VBD the/DT nisoldipine/NN plasma/NN concentrations/NNS to/TO undetectable/JJ levels/NNS ./.


DrugDDI.d234
DrugDDI.d234.s4
Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.

Coadministration/NN of/IN SULAR/NN with/IN phenytoin/NN or/CC any/DT known/JJ CYP3A4/NN inducer/NN should/MD be/VB avoided/VBN and/CC alternative/JJ antihypertensive/JJ therapy/NN should/MD be/VB considered/VBN ./.


DrugDDI.d234
DrugDDI.d234.s5
Pharmacokinetic interactions between nisoldipine and beta-blockers ( atenolol , propranolol ) were variable and not significant.

Pharmacokinetic/JJ interactions/NNS between/IN nisoldipine/NN and/CC beta-blockers/NNS (/-LRB- atenolol/NN ,/, propranolol/NN )/-RRB- were/VBD variable/JJ and/CC not/RB significant/JJ ./.


DrugDDI.d234
DrugDDI.d234.s6
Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine .

Propranolol/NN attenuated/VBD the/DT heart/NN rate/NN increase/NN following/VBG administration/NN of/IN immediate/JJ release/NN nisoldipine/NN ./.


DrugDDI.d234
DrugDDI.d234.s7
The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.

The/DT blood/NN pressure/NN effect/NN of/IN SULAR/NN tended/VBD to/TO be/VB greater/JJR in/IN patients/NNS on/IN atenolol/NN than/IN in/IN patients/NNS on/IN no/DT other/JJ antihypertensive/JJ therapy/NN ./.


DrugDDI.d234
DrugDDI.d234.s8
Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.

Quinidine/NN at/IN 648/CD mg/NN bid/NN decreased/VBD the/DT bioavailability/NN (/-LRB- AUC/NN )/-RRB- of/IN nisoldipine/NN by/IN 26/CD %/NN ,/, but/CC not/RB the/DT peak/JJ concentration/NN ./.


DrugDDI.d234
DrugDDI.d234.s9
The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.

The/DT immediate/JJ release/NN ,/, but/CC not/RB the/DT coat-core/JJ formulation/NN of/IN nisoldipine/NN increased/VBD plasma/NN quinidine/NN concentrations/NNS by/IN about/RB 20/CD %./NN


DrugDDI.d234
DrugDDI.d234.s11
No significant interactions were found between nisoldipine and warfarin or digoxin .

No/DT significant/JJ interactions/NNS were/VBD found/VBN between/IN nisoldipine/NN and/CC warfarin/NN or/CC digoxin/NN ./.


DrugDDI.d306
DrugDDI.d306.s0
Tizoxanide is highly bound to plasma protein ( 99.9%).

Tizoxanide/NN is/VBZ highly/RB bound/VBN to/TO plasma/NN protein/NN (/-LRB- 99.9/CD %)./NN


DrugDDI.d306
DrugDDI.d306.s1
Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin ).

Therefore/RB ,/, caution/NN should/MD be/VB used/VBN when/WRB administering/VBG nitazoxanide/NN concurrently/RB with/IN other/JJ highly/RB plasma/NN protein-bound/JJ drugs/NNS with/IN narrow/JJ therapeutic/JJ indices/NNS ,/, as/IN competition/NN for/IN binding/NN sites/NNS may/MD occur/VB (/-LRB- e.g./FW ,/, warfarin/NN )/-RRB- ./.


DrugDDI.d306
DrugDDI.d306.s2
In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.

In/FW vitro/FW metabolism/NN studies/NNS have/VBP demonstrated/VBN that/IN tizoxanide/NN has/VBZ no/DT significant/JJ inhibitory/JJ effect/NN on/IN cytochrome/NN P450/NN enzymes/NNS ./.


DrugDDI.d306
DrugDDI.d306.s3
Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.

Although/IN no/DT drug-drug/JJ interaction/NN studies/NNS have/VBP been/VBN conducted/VBN in/FW vivo/FW ,/, it/PRP is/VBZ expected/VBN that/IN no/DT significant/JJ interaction/NN would/MD occur/VB when/WRB nitazoxanide/NN is/VBZ co-administered/VBN with/IN drugs/NNS that/WDT either/RB are/VBP metabolized/VBN by/IN or/CC inhibit/VB cytochrome/NN P450/NN enzymes/NNS ./.


DrugDDI.d20
DrugDDI.d20.s0
Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4 /5 with potentially important effects on plasma concentrations of other drugs .

Oxcarbazepine/NN can/MD inhibit/VB CYP2C19/NN and/CC induce/VB CYP3A4/NN /5/NN with/IN potentially/RB important/JJ effects/NNS on/IN plasma/NN concentrations/NNS of/IN other/JJ drugs/NNS ./.


DrugDDI.d20
DrugDDI.d20.s1
In addition, several AED@s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.

In/IN addition/NN ,/, several/JJ AED/JJ @/NN s/NNS that/WDT are/VBP cytochrome/NN P450/NN inducers/NNS can/MD decrease/VB plasma/NN concentrations/NNS of/IN oxcarbazepine/NN and/CC MHD/NN ./.


DrugDDI.d20
DrugDDI.d20.s2
Oxcarbazepine was evaluated in human liver microsomes to determine its capacity to inhibit the major cytochrome P450 enzymes responsible for the metabolism of other drugs .

Oxcarbazepine/NN was/VBD evaluated/VBN in/IN human/JJ liver/NN microsomes/NNS to/TO determine/VB its/PRP$ capacity/NN to/TO inhibit/VB the/DT major/JJ cytochrome/NN P450/NN enzymes/NNS responsible/JJ for/IN the/DT metabolism/NN of/IN other/JJ drugs/NNS ./.


DrugDDI.d20
DrugDDI.d20.s3
Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated ( CYP1A2 , CYP2A6 , CYP2C9 , CYP2D6 , CYP2E1 , CYP4A9 and CYP4A11 ) with the exception of CYP2C19 and CYP3A4 /5.

Results/NNS demonstrate/VBP that/IN oxcarbazepine/NN and/CC its/PRP$ pharmacologically/RB active/JJ 10-monohydroxy/NN metabolite/NN (/-LRB- MHD/NN )/-RRB- have/VBP little/JJ or/CC no/DT capacity/NN to/TO function/VB as/IN inhibitors/NNS for/IN most/JJS of/IN the/DT human/JJ cytochrome/NN P450/NN enzymes/NNS evaluated/VBN (/-LRB- CYP1A2/NN ,/, CYP2A6/NN ,/, CYP2C9/NN ,/, CYP2D6/NN ,/, CYP2E1/NN ,/, CYP4A9/NN and/CC CYP4A11/NN )/-RRB- with/IN the/DT exception/NN of/IN CYP2C19/NN and/CC CYP3A4/NN /5/NN ./.


DrugDDI.d20
DrugDDI.d20.s4
Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.

Although/IN inhibition/NN of/IN CYP/NN 3A4/5/NN by/IN OXC/NN and/CC MHD/NN did/VBD occur/VB at/IN high/JJ concentrations/NNS ,/, it/PRP is/VBZ not/RB likely/JJ to/TO be/VB of/IN clinical/JJ significance/NN ./.


DrugDDI.d20
DrugDDI.d20.s5
The inhibition of CYP-2C19 by OXC and MHD, however, is clinically relevant.

The/DT inhibition/NN of/IN CYP-2C19/NN by/IN OXC/NN and/CC MHD/NN ,/, however/RB ,/, is/VBZ clinically/RB relevant/JJ ./.


DrugDDI.d20
DrugDDI.d20.s6
In vitro, the UDP-glucuronyl transferase level was increased, indicating induction of this enzyme.

In/FW vitro/FW ,/, the/DT UDP-glucuronyl/JJ transferase/NN level/NN was/VBD increased/VBN ,/, indicating/VBG induction/NN of/IN this/DT enzyme/NN ./.


DrugDDI.d20
DrugDDI.d20.s7
Increases of 22% with MHD and 47% with oxcarbazepine were observed.

Increases/NNS of/IN 22/CD %/NN with/IN MHD/NN and/CC 47/CD %/NN with/IN oxcarbazepine/NN were/VBD observed/VBN ./.


DrugDDI.d20
DrugDDI.d20.s8
As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase , it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid , lamotrigine ).

As/IN MHD/NN ,/, the/DT predominant/JJ plasma/NN substrate/NN ,/, is/VBZ only/RB a/DT weak/JJ inducer/NN of/IN UDP-glucuronyl/NN transferase/NN ,/, it/PRP is/VBZ unlikely/JJ to/TO have/VB an/DT effect/NN on/IN drugs/NNS that/WDT are/VBP mainly/RB eliminated/VBN by/IN conjugation/NN through/IN UDP-glucuronyl/JJ transferase/NN (/-LRB- e.g./FW ,/, valproic/JJ acid/NN ,/, lamotrigine/NN )/-RRB- ./.


DrugDDI.d20
DrugDDI.d20.s9
In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family ( CYP3A4 and CYP3A5 ) responsible for the metabolism of dihydropyridine calcium antagonist s and oral contraceptives , resulting in a lower plasma concentration of these drugs .

In/IN addition/NN ,/, oxcarbazepine/NN and/CC MHD/NN induce/VBP a/DT subgroup/NN of/IN the/DT cytochrome/NN P450/NN 3A/NN family/NN (/-LRB- CYP3A4/NN and/CC CYP3A5/NN )/-RRB- responsible/JJ for/IN the/DT metabolism/NN of/IN dihydropyridine/NN calcium/NN antagonist/NN s/NN and/CC oral/JJ contraceptives/NNS ,/, resulting/VBG in/IN a/DT lower/JJR plasma/NN concentration/NN of/IN these/DT drugs/NNS ./.


DrugDDI.d20
DrugDDI.d20.s10
As binding of MHD to plasma proteins is low (40%), clinically significant interactions with other drugs through competition for protein binding sites are unlikely.

As/IN binding/NN of/IN MHD/NN to/TO plasma/NN proteins/NNS is/VBZ low/JJ (/-LRB- 40/CD %/NN )/-RRB- ,/, clinically/RB significant/JJ interactions/NNS with/IN other/JJ drugs/NNS through/IN competition/NN for/IN protein/NN binding/NN sites/NNS are/VBP unlikely/JJ ./.


DrugDDI.d20
DrugDDI.d20.s11
Antiepileptic drugs Potential interactions between Trileptal and other AEDs were assessed in clinical studies.

Antiepileptic/JJ drugs/NNS Potential/JJ interactions/NNS between/IN Trileptal/NNP and/CC other/JJ AEDs/NNS were/VBD assessed/VBN in/IN clinical/JJ studies/NNS ./.


DrugDDI.d20
DrugDDI.d20.s12
The effect of these interactions on mean AUCs and Cmin are summarized in Table 2: Table 2: Summary of AED interactions with Trileptal .

The/DT effect/NN of/IN these/DT interactions/NNS on/IN mean/JJ AUCs/NNS and/CC Cmin/NN are/VBP summarized/VBN in/IN Table/NN 2/CD :/: Table/NN 2/CD :/: Summary/NN of/IN AED/JJ interactions/NNS with/IN Trileptal/NN ./.


DrugDDI.d20
DrugDDI.d20.s15
Trileptal dose (mg/day) .

Trileptal/JJ dose/NN (/-LRB- mg/day/NN )/-RRB- ./.


DrugDDI.d20
DrugDDI.d20.s16
Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval) .

Influence/NN of/IN Trileptal/NN on/IN AED/JJ Concentration/NN (/-LRB- Mean/NN change/NN ,/, 90/CD %/NN Confidence/NN Interval/NN )/-RRB- ./.


DrugDDI.d20
DrugDDI.d20.s18
Carbamazepine .

Carbamazepine/NN ./.


DrugDDI.d20
DrugDDI.d20.s22
Phenobarbital .

Phenobarbital/NN ./.


DrugDDI.d20
DrugDDI.d20.s26
Phenytoin .

Phenytoin/NN ./.


DrugDDI.d20
DrugDDI.d20.s31
Valproic acid .

Valproic/JJ acid/NN ./.


DrugDDI.d20
DrugDDI.d20.s35
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.

1-/CD nc/NN denotes/VBZ a/DT mean/JJ change/NN of/IN less/JJR than/IN 10/CD %/NN 2-/CD Pediatrics/NN 3-/CD Mean/NN increase/NN in/IN adults/NNS at/IN high/JJ Trileptal/NN doses/NNS In/FW vivo/FW ,/, the/DT plasma/NN levels/NNS of/IN phenytoin/NN increased/VBD by/IN up/RB to/TO 40/CD %/NN ,/, when/WRB Trileptal/NN was/VBD given/VBN at/IN doses/NNS above/IN 1200/CD mg/day/NN ./.


DrugDDI.d20
DrugDDI.d20.s36
Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.

Therefore/RB ,/, when/WRB using/VBG doses/NNS of/IN Trileptal/NN greater/JJR than/IN 1200/CD mg/day/NN during/IN adjunctive/JJ therapy/NN ,/, a/DT decrease/NN in/IN the/DT dose/NN of/IN phenytoin/NN may/MD be/VB required/VBN ./.


DrugDDI.d20
DrugDDI.d20.s37
The increase of phenobarbital level, however, is small (15%) when given with Trileptal .

The/DT increase/NN of/IN phenobarbital/NN level/NN ,/, however/RB ,/, is/VBZ small/JJ (/-LRB- 15/CD %/NN )/-RRB- when/WRB given/VBN with/IN Trileptal/NN ./.


DrugDDI.d20
DrugDDI.d20.s38
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine , phenytoin and phenobarbital ) have been shown to decrease the plasma levels of MHD (29-40%).

Strong/JJ inducers/NNS of/IN cytochrome/NN P450/NN enzymes/NNS (/-LRB- i.e./FW carbamazepine/NN ,/, phenytoin/NN and/CC phenobarbital/NN )/-RRB- have/VBP been/VBN shown/VBN to/TO decrease/VB the/DT plasma/NN levels/NNS of/IN MHD/NN (/-LRB- 29-40%)./NN


DrugDDI.d20
DrugDDI.d20.s39
No autoinduction has been observed with Trileptal .

No/DT autoinduction/NN has/VBZ been/VBN observed/VBN with/IN Trileptal/NN ./.


DrugDDI.d20
DrugDDI.d20.s40
Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).

Hormonal/JJ contraceptives/NNS Co-administration/NN of/IN Trileptal/NN with/IN an/DT oral/JJ contraceptive/NN has/VBZ been/VBN shown/VBN to/TO influence/VB the/DT plasma/NN concentrations/NNS of/IN the/DT two/CD hormonal/JJ components/NNS ,/, ethinylestradiol/NN (/-LRB- EE/NN )/-RRB- and/CC levonorgestrel/NN (/-LRB- LNG)./NN


DrugDDI.d20
DrugDDI.d20.s43
Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.

Therefore/RB ,/, concurrent/JJ use/NN of/IN Trileptal/NN with/IN hormonal/JJ contraceptives/NNS may/MD render/VB these/DT contraceptives/NNS less/RBR effective/JJ ./.


DrugDDI.d20
DrugDDI.d20.s44
Studies with other oral or implant contraceptives have not been conducted.

Studies/NNS with/IN other/JJ oral/JJ or/CC implant/JJ contraceptives/NNS have/VBP not/RB been/VBN conducted/VBN ./.


DrugDDI.d20
DrugDDI.d20.s45
Calcium Antagonist s After repeated co-administration of Trileptal , the AUC of felodipine was lowered by 28% [90% CI: 20-33].

Calcium/NN Antagonist/NN s/NN After/IN repeated/JJ co-administration/NN of/IN Trileptal/NN ,/, the/DT AUC/NN of/IN felodipine/NN was/VBD lowered/VBN by/IN 28/CD %/NN [90/CD %/NN CI/NN :/: 20-33/CD ]./NN


DrugDDI.d20
DrugDDI.d20.s46
Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.

Verapamil/NN produced/VBD a/DT decrease/NN of/IN 20/CD %/NN [90/CD %/NN CI/CD :/: 18-27/CD ]/-RRB- of/IN the/DT plasma/NN levels/NNS of/IN MHD/NN ./.


DrugDDI.d20
DrugDDI.d20.s47
Other drug interactions Cimetidine , erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.

Other/JJ drug/NN interactions/NNS Cimetidine/NN ,/, erythromycin/NN and/CC dextropropoxyphene/NN had/VBD no/DT effect/NN on/IN the/DT pharmacokinetics/NNS of/IN MHD/NN ./.


DrugDDI.d20
DrugDDI.d20.s48
Results with warfarin wshow no evidence of interaction with either single or repeated doses of Trileptal .

Results/NNS with/IN warfarin/NN wshow/VBP no/DT evidence/NN of/IN interaction/NN with/IN either/CC single/JJ or/CC repeated/JJ doses/NNS of/IN Trileptal/NN ./.


DrugDDI.d480
DrugDDI.d480.s0
In a Phase : I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin ).

In/IN a/DT Phase/NN :/: I/NN trial/NN using/VBG escalating/JJ doses/NNS of/IN TAXOL/NN (/-LRB- 110-200/CD mg/m2/NN )/-RRB- and/CC cisplatin/NN (/-LRB- 50/CD or/CC 75/CD mg/m2/NN )/-RRB- given/VBN as/IN sequential/JJ infusions/NNS ,/, myelosuppression/NN was/VBD more/RBR profound/JJ when/WRB TAXOL/NN was/VBD given/VBN after/IN cisplatin/NN than/IN with/IN the/DT alternate/JJ sequence/NN (/-LRB- ie/FW ,/, TAXOL/NN before/IN cisplatin/NN )/-RRB- ./.


DrugDDI.d480
DrugDDI.d480.s1
Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin .

Pharmacokinetic/JJ data/NNS from/IN these/DT patients/NNS demonstrated/VBD a/DT decrease/NN in/IN paclitaxel/NN clearance/NN of/IN approximately/RB 33/CD %/NN when/WRB TAXOL/NN was/VBD administered/VBN following/VBG cisplatin/NN ./.


DrugDDI.d480
DrugDDI.d480.s2
The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4 .

The/DT metabolism/NN of/IN TAXOL/NN is/VBZ catalyzed/VBN by/IN cytochrome/NN P450/NN isoen-zymes/NNS CYP2C8/NN and/CC CYP3A4/NN ./.


DrugDDI.d480
DrugDDI.d480.s3
In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4 .

In/IN the/DT absence/NN of/IN formal/JJ clinical/JJ drug/NN interaction/NN studies/NNS ,/, caution/NN should/MD be/VB exercised/VBN when/WRB administering/VBG TAXOL/NN concomitantly/RB with/IN known/JJ substrates/NNS or/CC inhibitors/NNS of/IN the/DT cytochrome/NN P450/NN isoenzymes/NNS CYP2C8/NN and/CC CYP3A4/NN ./.


DrugDDI.d480
DrugDDI.d480.s4
Potential interactions between TAXOL , a substrate of CYP3A4 , and protease inhibitors ( ritonavir , saquinavir , indinavir , and nelfinavir ), which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials.

Potential/JJ interactions/NNS between/IN TAXOL/NN ,/, a/DT substrate/NN of/IN CYP3A4/NN ,/, and/CC protease/NN inhibitors/NNS (/-LRB- ritonavir/NN ,/, saquinavir/NN ,/, indinavir/NN ,/, and/CC nelfinavir/NN )/-RRB- ,/, which/WDT are/VBP substrates/NNS and/or/CC inhibitors/NNS of/IN CYP3A4/NN ,/, have/VBP not/RB been/VBN evaluated/VBN in/IN clinical/JJ trials/NNS ./.


DrugDDI.d480
DrugDDI.d480.s5
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.

Reports/NNS in/IN the/DT literature/NN suggest/VBP that/IN plasma/NN levels/NNS of/IN doxorubicin/NN (/-LRB- and/CC its/PRP$ active/JJ metabolite/NN doxorubicinol/NN )/-RRB- may/MD be/VB increased/VBN when/WRB paclitaxel/NN and/CC doxorubicin/NN are/VBP used/VBN in/IN combination/NN ./.


DrugDDI.d480
DrugDDI.d480.s6
Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3.

Hematology/NNP :/: TAXOL/NN therapy/NN should/MD not/RB be/VB administered/VBN to/TO patients/NNS with/IN baseline/NN neutrophil/NN counts/NNS of/IN less/JJR than/IN 1,500/CD cells/mm3/NN ./.


DrugDDI.d480
DrugDDI.d480.s7
In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL .

In/IN order/NN to/TO monitor/VB the/DT occurrence/NN of/IN myelotoxicity/NN ,/, it/PRP is/VBZ recommended/VBN that/IN frequent/JJ peripheral/JJ blood/NN cell/NN counts/NNS be/VB performed/VBN on/IN all/DT patients/NNS receiving/VBG TAXOL/NN ./.


DrugDDI.d480
DrugDDI.d480.s8
Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level 1500 cells/mm3 and platelets recover to a level 100,000 cells/mm3.

Patients/NNS should/MD not/RB be/VB re-treated/VBN with/IN subsequent/JJ cycles/NNS of/IN TAXOL/NN until/IN neutrophils/NNS recover/VBP to/TO a/DT level/NN 1500/CD cells/mm3/NN and/CC platelets/NNS recover/VBP to/TO a/DT level/NN 100,000/CD cells/mm3/NN ./.


DrugDDI.d480
DrugDDI.d480.s9
In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended.

In/IN the/DT case/NN of/IN severe/JJ neutropenia/NN (/-LRB- 500/CD cells/mm3/NN for/IN seven/CD days/NNS or/CC more/JJR )/-RRB- during/IN a/DT course/NN of/IN TAXOL/NN therapy/NN ,/, a/DT 20/CD %/NN reduction/NN in/IN dose/NN for/IN subsequent/JJ courses/NNS of/IN therapy/NN is/VBZ recommended/VBN ./.


DrugDDI.d480
DrugDDI.d480.s10
For patients with advanced HIV disease and poor-risk AIDS-related Kaposi@s sarcoma, TAXOL , at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3.

For/IN patients/NNS with/IN advanced/JJ HIV/NN disease/NN and/CC poor-risk/JJ AIDS-related/JJ Kaposi/NN @/NN s/NN sarcoma/NN ,/, TAXOL/NN ,/, at/IN the/DT recommended/VBN dose/NN for/IN this/DT disease/NN ,/, can/MD be/VB initiated/VBN and/CC repeated/VBN if/IN the/DT neutrophil/NN count/NN is/VBZ at/IN least/JJS 1000/CD cells/mm3/NN ./.


DrugDDI.d480
DrugDDI.d480.s11
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor@ EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL .

Hypersensitivity/NN Reactions/NNS :/: Patients/NNS with/IN a/DT history/NN of/IN severe/JJ hypersensitivity/NN reactions/NNS to/TO products/NNS containing/VBG Cremophor/NN @/NN EL/NN (/-LRB- eg/NN ,/, cyclosporin/NN for/IN injection/NN concentrate/NN and/CC teniposide/NN for/IN injection/NN concentrate/NN )/-RRB- should/MD not/RB be/VB treated/VBN with/IN TAXOL/NN ./.


DrugDDI.d480
DrugDDI.d480.s12
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone ), diphen -hydramine and H2 antagonists (such as cimetidine or ranitidine ).

In/IN order/NN to/TO avoid/VB the/DT occurrence/NN of/IN severe/JJ hypersensitivity/NN reactions/NNS ,/, all/DT patients/NNS treated/VBN with/IN TAXOL/NN should/MD be/VB premedicated/VBN with/IN corticosteroids/NNS (/-LRB- such/JJ as/IN dexamethasone/NN )/-RRB- ,/, diphen/NN -hydramine/NN and/CC H2/NN antagonists/NNS (/-LRB- such/JJ as/IN cimetidine/NN or/CC ranitidine/NN )/-RRB- ./.


DrugDDI.d480
DrugDDI.d480.s14
However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators , angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.

However/RB ,/, severe/JJ reactions/NNS ,/, such/JJ as/IN hypotension/NN requiring/VBG treatment/NN ,/, dyspnea/NN requiring/VBG bronchodilators/NNS ,/, angioedema/NN ,/, or/CC generalized/JJ urticaria/NN require/VBP immediate/JJ discontinuation/NN of/IN TAXOL/NN and/CC aggressive/JJ symptomatic/JJ therapy/NN ./.


DrugDDI.d480
DrugDDI.d480.s15
Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL .

Patients/NNS who/WP have/VBP developed/VBN severe/JJ hypersensitivity/NN reactions/NNS should/MD not/RB be/VB rechallenged/VBN with/IN TAXOL/NN ./.


DrugDDI.d480
DrugDDI.d480.s16
Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL , but generally do not require treatment.

Cardiovascular/NN :/: Hypotension/NN ,/, bradycardia/NN ,/, and/CC hypertension/NN have/VBP been/VBN observed/VBN during/IN administration/NN of/IN TAXOL/NN ,/, but/CC generally/RB do/VBP not/RB require/VB treatment/NN ./.


DrugDDI.d480
DrugDDI.d480.s17
Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension.

Occasionally/RB TAXOL/NN infusions/NNS must/MD be/VB interrupted/VBN or/CC discontinued/VBD because/IN of/IN initial/JJ or/CC recurrent/JJ hypertension/NN ./.


DrugDDI.d480
DrugDDI.d480.s18
Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended.

Frequent/JJ vital/JJ sign/NN monitoring/NN ,/, particularly/RB during/IN the/DT first/JJ hour/NN of/IN TAXOL/NN infusion/NN ,/, is/VBZ recommended/VBN ./.


DrugDDI.d480
DrugDDI.d480.s20
Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL .

Nervous/JJ System/NN :/: Although/IN the/DT occurrence/NN of/IN peripheral/JJ neuropathy/NN is/VBZ frequent/JJ ,/, the/DT development/NN of/IN severe/JJ symptomatology/NN is/VBZ unusual/JJ and/CC requires/VBZ a/DT dose/NN reduction/NN of/IN 20/CD %/NN for/IN all/DT subsequentcourses/NNS of/IN TAXOL/NN ./.


DrugDDI.d480
DrugDDI.d480.s21
TAXOL contains dehydrated alcohol USP , 396 mg/mL; .

TAXOL/NN contains/VBZ dehydrated/JJ alcohol/NN USP/NN ,/, 396/CD mg/mL/NN ;/: ./.


DrugDDI.d480
DrugDDI.d480.s22
consideration should be given to possible CNS and other effects of alcohol .

consideration/NN should/MD be/VB given/VBN to/TO possible/JJ CNS/NNS and/CC other/JJ effects/NNS of/IN alcohol/NN ./.


DrugDDI.d480
DrugDDI.d480.s23
Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin 2 times ULN.

Hepatic/JJ :/: There/EX is/VBZ limited/JJ evidence/NN that/IN the/DT myelotoxicity/NN of/IN TAXOL/NN may/MD be/VB exacerbated/JJ in/IN patients/NNS with/IN serum/NN total/JJ bilirubin/NN 2/CD times/NNS ULN/NN ./.


DrugDDI.d480
DrugDDI.d480.s24
Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17.

Extreme/JJ caution/NN should/MD be/VB exercised/VBN when/WRB administering/VBG TAXOL/NN to/TO such/JJ patients/NNS ,/, with/IN dose/NN reduction/NN as/IN recommended/VBN in/IN DOSAGE/NN AND/CC ADMINISTRATION/NN ,/, Table/NN 17/CD ./.


DrugDDI.d480
DrugDDI.d480.s27
Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely.

Recurrence/NN of/IN skin/NN reactions/NNS at/IN a/DT site/NN of/IN previous/JJ extravasation/NN following/VBG administration/NN of/IN TAXOL/NN at/IN a/DT different/JJ site/NN ,/, ie/FW ,/, recall/NN ,/, has/VBZ been/VBN reported/VBN rarely/RB ./.


DrugDDI.d480
DrugDDI.d480.s28
Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety.

Rare/JJ reports/NNS of/IN more/RBR severe/JJ events/NNS such/JJ as/IN phlebitis/NN ,/, cellulitis/NN ,/, induration/NN ,/, skin/NN exfoliation/NN ,/, necrosis/NN ,/, and/CC fibrosis/NN have/VBP been/VBN received/VBN as/IN part/NN of/IN the/DT continuing/VBG surveillance/NN of/IN TAXOL/NN safety/NN ./.


DrugDDI.d235
DrugDDI.d235.s0
Aminoglycosides : The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside .

Aminoglycosides/NNS :/: The/DT mixing/NN of/IN piperacillin/NN with/IN an/DT aminoglycoside/NN in/IN vitro/FW can/MD result/VB in/IN substantial/JJ inactivation/NN of/IN the/DT aminoglycoside/NN ./.


DrugDDI.d235
DrugDDI.d235.s1
Vecuronium : When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium .

Vecuronium/NN :/: When/WRB used/VBN in/IN the/DT perioperative/JJ period/NN ,/, piperacillin/NN has/VBZ been/VBN implicated/VBN in/IN the/DT prolongation/NN of/IN the/DT neuromuscular/JJ blockade/NN of/IN vecuronium/NN ./.


DrugDDI.d235
DrugDDI.d235.s2
Caution is indicated when piperacillin is used perioperatively.

Caution/NN is/VBZ indicated/VBN when/WRB piperacillin/NN is/VBZ used/VBN perioperatively/NN ./.


DrugDDI.d235
DrugDDI.d235.s3
In one controlled clinical study, the ureidopenicillins, including piperacillin , were reported to prolong the action of vecuronium .

In/IN one/CD controlled/JJ clinical/JJ study/NN ,/, the/DT ureidopenicillins/NNS ,/, including/VBG piperacillin/NN ,/, were/VBD reported/VBN to/TO prolong/VB the/DT action/NN of/IN vecuronium/NN ./.


DrugDDI.d235
DrugDDI.d235.s4
Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin .

Due/JJ to/TO their/PRP$ similar/JJ mechanism/NN of/IN action/NN ,/, it/PRP is/VBZ expected/VBN that/IN the/DT neuromuscular/JJ blockade/NN produced/VBN by/IN any/DT of/IN the/DT non-depolarizing/JJ muscle/NN relaxants/NNS could/MD be/VB prolonged/VBD in/IN the/DT presence/NN of/IN piperacillin/NN ./.


DrugDDI.d235
DrugDDI.d235.s5
Probenecid : The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.

Probenecid/NN :/: The/DT oral/JJ combination/NN of/IN probenecid/NN before/IN intramuscular/JJ injection/NN of/IN PIPRACIL/NN produces/VBZ an/DT increase/NN in/IN piperacillin/JJ peak/JJ serum/NN level/NN of/IN about/RB 30/CD %./NN


DrugDDI.d235
DrugDDI.d235.s6
Anticoagulants Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin , oral anticoagulants , or other drugs that may affect the blood coagulation system or the thrombocyte function.

Anticoagulants/NNS Coagulation/NN parameters/NNS should/MD be/VB tested/VBN more/RBR frequently/RB and/CC monitored/VBN regularly/RB during/IN simultaneous/JJ administration/NN of/IN high/JJ doses/NNS of/IN heparin/NN ,/, oral/JJ anticoagulants/NNS ,/, or/CC other/JJ drugs/NNS that/WDT may/MD affect/VB the/DT blood/NN coagulation/NN system/NN or/CC the/DT thrombocyte/JJ function/NN ./.


DrugDDI.d235
DrugDDI.d235.s7
Methotrexate Piperacillin sodium may reduce the excretion of methotrexate .

Methotrexate/NN Piperacillin/NN sodium/NN may/MD reduce/VB the/DT excretion/NN of/IN methotrexate/NN ./.


DrugDDI.d235
DrugDDI.d235.s8
Therefore, serum levels of methotrexate should be monitored in patients to avoid drug toxicity.

Therefore/RB ,/, serum/NN levels/NNS of/IN methotrexate/NN should/MD be/VB monitored/VBN in/IN patients/NNS to/TO avoid/VB drug/NN toxicity/NN ./.


DrugDDI.d235
DrugDDI.d235.s9
Drug /Laboratory Test Interactions : As with other penicillins , the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper -reduction method.

Drug/NN /Laboratory/NN Test/NN Interactions/NNS :/: As/IN with/IN other/JJ penicillins/NNS ,/, the/DT administration/NN of/IN PIPRACIL/NN may/MD result/VB in/IN a/DT false-positive/JJ reaction/NN for/IN glucose/NN in/IN the/DT urine/NN using/VBG a/DT copper/NN -reduction/NN method/NN ./.


DrugDDI.d235
DrugDDI.d235.s10
It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

It/PRP is/VBZ recommended/VBN that/IN glucose/NN tests/NNS based/VBN on/IN enzymatic/JJ glucose/NN oxidase/NN reactions/NNS be/VB used/VBN ./.


DrugDDI.d235
DrugDDI.d235.s11
There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin / tazobactam injection who were subsequently found to be free of Aspergillus infection.

There/EX have/VBP been/VBN reports/NNS of/IN positive/JJ test/NN results/NNS using/VBG the/DT Bio-Rad/JJ Laboratories/NNS Platelia/NN Aspergillus/NN EIA/NN test/NN in/IN patients/NNS receiving/VBG piperacillin/NN //: tazobactam/NN injection/NN who/WP were/VBD subsequently/RB found/VBN to/TO be/VB free/JJ of/IN Aspergillus/JJ infection/NN ./.


DrugDDI.d235
DrugDDI.d235.s12
Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported.

Cross-reactions/NNS with/IN non-Aspergillus/JJ polysaccharides/NNS and/CC polyfuranoses/NNS with/IN the/DT Bio-Rad/JJ Laboratories/NNS Platelia/FW Aspergillus/FW EIA/NN test/NN have/VBP been/VBN reported/VBN ./.


DrugDDI.d235
DrugDDI.d235.s13
Therefore, positive test results in patients receiving piperacillin should be interpreted cautiously and confirmed by other diagnostic methods.

Therefore/RB ,/, positive/JJ test/NN results/NNS in/IN patients/NNS receiving/VBG piperacillin/NN should/MD be/VB interpreted/VBN cautiously/RB and/CC confirmed/VBN by/IN other/JJ diagnostic/JJ methods/NNS ./.


DrugDDI.d253
DrugDDI.d253.s0
Effect of other drugs on Vardenafil .

Effect/NN of/IN other/JJ drugs/NNS on/IN Vardenafil/NN ./.


DrugDDI.d253
DrugDDI.d253.s1
In vitro studies: Studies in human liver microsomes showed that vardenafil is metabolized primarily by cytochrome P450 ( CYP ) isoforms 3A4/5, and to a lesser degree by CYP2C9 .

In/FW vitro/FW studies/NNS :/: Studies/NNS in/IN human/JJ liver/NN microsomes/NNS showed/VBD that/IN vardenafil/NN is/VBZ metabolized/VBN primarily/RB by/IN cytochrome/NN P450/NN (/-LRB- CYP/NN )/-RRB- isoforms/NNS 3A4/5/NN ,/, and/CC to/TO a/DT lesser/JJR degree/NN by/IN CYP2C9/NN ./.


DrugDDI.d253
DrugDDI.d253.s2
Therefore, inhibitors of these enzymes are expected to reduce vardenafil clearance.

Therefore/RB ,/, inhibitors/NNS of/IN these/DT enzymes/NNS are/VBP expected/VBN to/TO reduce/VB vardenafil/NN clearance/NN ./.


DrugDDI.d253
DrugDDI.d253.s3
In vivo studies: Cytochrome P450 Inhibitors .

In/FW vivo/FW studies/NNS :/: Cytochrome/NN P450/NN Inhibitors/NNS ./.


DrugDDI.d253
DrugDDI.d253.s4
Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.

Cimetidine/NN (/-LRB- 400/CD mg/NN b.i.d./NN )/-RRB- had/VBD no/DT effect/NN on/IN vardenafil/NN bioavailability/NN (/-LRB- AUC/NN )/-RRB- and/CC maximum/NN concentration/NN (/-LRB- Cmax/NN )/-RRB- of/IN vardenafil/NN when/WRB co-administered/VBN with/IN 20/CD mg/NN Vardenafil/NN in/IN healthy/JJ volunteers/NNS ./.


DrugDDI.d253
DrugDDI.d253.s5
Erythromycin ( 500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.

Erythromycin/NN (/-LRB- 500/CD mg/NN t.i.d/CD )/-RRB- produced/VBD a/DT 4-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN and/CC a/DT 3-fold/JJ increase/NN in/IN Cmax/NN when/WRB co-administered/VBN with/IN Vardenafil/NN 5/CD mg/NN in/IN healthy/JJ volunteers/NNS ./.


DrugDDI.d253
DrugDDI.d253.s6
It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin .

It/PRP is/VBZ recommended/VBN not/RB to/TO exceed/VB a/DT single/JJ 5/CD mg/NN dose/NN of/IN Vardenafil/NN in/IN a/DT 24-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN erythromycin/NN ./.


DrugDDI.d253
DrugDDI.d253.s7
Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.

Ketoconazole/NN (/-LRB- 200/CD mg/NN once/RB daily/JJ )/-RRB- produced/VBD a/DT 10-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN and/CC a/DT 4-fold/JJ increase/NN in/IN Cmax/NN when/WRB co-administered/VBN with/IN Vardenafil/NN (/-LRB- 5/CD mg/NN )/-RRB- in/IN healthy/JJ volunteers/NNS ./.


DrugDDI.d253
DrugDDI.d253.s8
A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole .

A/DT 5-mg/JJ Vardenafil/NN dose/NN should/MD not/RB be/VB exceeded/VBD when/WRB used/VBN in/IN combination/NN with/IN 200/CD mg/NN once/IN daily/JJ ketoconazole/NN ./.


DrugDDI.d253
DrugDDI.d253.s9
Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.

Since/IN higher/JJR doses/NNS of/IN ketoconazole/NN (/-LRB- 400/CD mg/NN daily/RB )/-RRB- may/MD result/VB in/IN higher/JJR increases/NNS in/IN Cmax/NN and/CC AUC/NN ,/, a/DT single/JJ 2.5/CD mg/NN dose/NN of/IN Vardenafil/NN should/MD not/RB be/VB exceeded/VBD in/IN a/DT 24-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN ketoconazole/NN 400/CD mg/NN daily/RB ./.


DrugDDI.d253
DrugDDI.d253.s10
HIV Protease Inhibitors : Indinavir ( 800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.

HIV/NN Protease/NN Inhibitors/NNS :/: Indinavir/NN (/-LRB- 800/CD mg/NN t.i.d./NN )/-RRB- co-administered/VBN with/IN Vardenafil/NN 10/CD mg/NN resulted/VBD in/IN a/DT 16-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN ,/, a/DT 7-fold/JJ increase/NN in/IN vardenafil/NN Cmax/NN and/CC a/DT 2-fold/JJ increase/NN in/IN vardenafil/NN half-life/NN ./.


DrugDDI.d253
DrugDDI.d253.s11
It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir .

It/PRP is/VBZ recommended/VBN not/RB to/TO exceed/VB a/DT single/JJ 2.5/CD mg/NN Vardenafil/NN dose/NN in/IN a/DT 24-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN indinavir/NN ./.


DrugDDI.d253
DrugDDI.d253.s12
Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.

Ritonavir/NN (/-LRB- 600/CD mg/NN b.i.d./NN )/-RRB- co-administered/VBN with/IN Vardenafil/NN 5/CD mg/NN resulted/VBD in/IN a/DT 49-fold/JJ increase/NN in/IN vardenafil/NN AUC/NN and/CC a/DT 13-fold/RB increase/NN in/IN vardenafil/NN Cmax/NN ./.


DrugDDI.d253
DrugDDI.d253.s13
The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir , a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9 .

The/DT interaction/NN is/VBZ a/DT consequence/NN of/IN blocking/VBG hepatic/JJ metabolism/NN of/IN vardenafil/NN by/IN ritonavir/NN ,/, a/DT highly/RB potent/JJ CYP3A4/NN inhibitor/NN ,/, which/WDT also/RB inhibits/VBZ CYP2C9/NN ./.


DrugDDI.d253
DrugDDI.d253.s14
Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.

Ritonavir/NN significantly/RB prolonged/VBD the/DT half-life/NN of/IN vardenafil/NN to/TO 26/CD hours/NNS ./.


DrugDDI.d253
DrugDDI.d253.s15
Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir .

Consequently/RB ,/, it/PRP is/VBZ recommended/VBN not/RB to/TO exceed/VB a/DT single/JJ 2.5/CD mg/NN Vardenafil/NN dose/NN in/IN a/DT 72-hour/JJ period/NN when/WRB used/VBN in/IN combination/NN with/IN ritonavir/NN ./.


DrugDDI.d253
DrugDDI.d253.s16
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs : glyburide , warfarin , digoxin , Maalox , and ranitidine .

Other/JJ Drug/NN Interactions/NNS :/: No/DT pharmacokinetic/JJ interactions/NNS were/VBD observed/VBN between/IN vardenafil/NN and/CC the/DT following/JJ drugs/NNS :/: glyburide/NN ,/, warfarin/NN ,/, digoxin/NN ,/, Maalox/NN ,/, and/CC ranitidine/NN ./.


DrugDDI.d253
DrugDDI.d253.s17
In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.

In/IN the/DT warfarin/JJ study/NN ,/, vardenafil/NN had/VBD no/DT effect/NN on/IN the/DT prothrombin/NN time/NN or/CC other/JJ pharmacodynamic/JJ parameters/NNS ./.


DrugDDI.d253
DrugDDI.d253.s18
Effects of Vardenafil on other drugs .

Effects/NNS of/IN Vardenafil/NN on/IN other/JJ drugs/NNS ./.


DrugDDI.d253
DrugDDI.d253.s19
In vitro studies: Vardenafil and its metabolites had no effect on CYP1A2 , 2A6, and 2E1 ( Ki 100uM ).

In/FW vitro/FW studies/NNS :/: Vardenafil/NN and/CC its/PRP$ metabolites/NNS had/VBD no/DT effect/NN on/IN CYP1A2/NN ,/, 2A6/NN ,/, and/CC 2E1/NN (/-LRB- Ki/NN 100uM/NN )/-RRB- ./.


DrugDDI.d253
DrugDDI.d253.s20
Weak inhibitory effects toward other isoforms ( CYP2C8 , 2C9, 2C19, 2D6, 3A4) were found, but Ki values were in excess of plasma concentrations achieved following dosing.

Weak/JJ inhibitory/JJ effects/NNS toward/IN other/JJ isoforms/NNS (/-LRB- CYP2C8/NN ,/, 2C9/NN ,/, 2C19/NN ,/, 2D6/NN ,/, 3A4/NN )/-RRB- were/VBD found/VBN ,/, but/CC Ki/NN values/NNS were/VBD in/IN excess/NN of/IN plasma/NN concentrations/NNS achieved/VBN following/VBG dosing/NN ./.


DrugDDI.d253
DrugDDI.d253.s21
The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 uM toward CYP3A4 , which is about 20 times higher than the M1 Cmax values after an 80 mg Vardenafil dose.

The/DT most/RBS potent/JJ inhibitory/JJ activity/NN was/VBD observed/VBN for/IN vardenafil/NN metabolite/NN M1/NN ,/, which/WDT had/VBD a/DT Ki/NN of/IN 1.4/CD uM/NN toward/IN CYP3A4/NN ,/, which/WDT is/VBZ about/RB 20/CD times/NNS higher/JJR than/IN the/DT M1/NN Cmax/NN values/NNS after/IN an/DT 80/CD mg/NN Vardenafil/NN dose/NN ./.


DrugDDI.d253
DrugDDI.d253.s22
In vivo studies: Nitrates : The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.

In/FW vivo/FW studies/NNS :/: Nitrates/NNS :/: The/DT blood/NN pressure/NN lowering/JJ effects/NNS of/IN sublingual/JJ nitrates/NNS (/-LRB- 0.4/CD mg/NN )/-RRB- taken/VBN 1/CD and/CC 4/CD hours/NNS after/IN vardenafil/NN and/CC increases/NNS in/IN heart/NN rate/NN when/WRB taken/VBN at/IN 1/CD ,/, 4/CD and/CC 8/CD hours/NNS were/VBD potentiated/VBN by/IN a/DT 20/CD mg/NN dose/NN of/IN Vardenafil/NN in/IN healthy/JJ middle-aged/JJ subjects/NNS ./.


DrugDDI.d253
DrugDDI.d253.s23
These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.

These/DT effects/NNS were/VBD not/RB observed/VBN when/WRB Vardenafil/NN 20/CD mg/NN was/VBD taken/VBN 24/CD hours/NNS before/IN the/DT NTG/NN ./.


DrugDDI.d253
DrugDDI.d253.s24
Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.

Potentiation/NN of/IN the/DT hypotensive/JJ effects/NNS of/IN nitrates/NNS for/IN patients/NNS with/IN ischemic/JJ heart/NN disease/NN has/VBZ not/RB been/VBN evaluated/VBN ,/, and/CC concomitant/JJ use/NN of/IN Vardenafil/NN and/CC nitrates/NNS is/VBZ contraindicated/VBN ./.


DrugDDI.d253
DrugDDI.d253.s25
Nifedipine : Vardenafil 20 mg , when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine , a drug that is metabolized via CYP3A4 .

Nifedipine/NN :/: Vardenafil/NN 20/CD mg/NN ,/, when/WRB co-administered/VBN with/IN slow-release/JJ nifedipine/NN 30/CD mg/NN or/CC 60/CD mg/NN once/RB daily/RB ,/, did/VBD not/RB affect/VB the/DT relative/JJ bioavailability/NN (/-LRB- AUC/NN )/-RRB- or/CC maximum/JJ concentration/NN (/-LRB- Cmax/NN )/-RRB- of/IN nifedipine/NN ,/, a/DT drug/NN that/WDT is/VBZ metabolized/VBN via/IN CYP3A4/NN ./.


DrugDDI.d253
DrugDDI.d253.s26
Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.

Nifedipine/NN did/VBD not/RB alter/VB the/DT plasma/NN levels/NNS of/IN Vardenafil/NN when/WRB taken/VBN in/IN combination/NN ./.


DrugDDI.d253
DrugDDI.d253.s27
In these patients whose hypertension was controlled with nifedipine , Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.

In/IN these/DT patients/NNS whose/WP$ hypertension/NN was/VBD controlled/VBN with/IN nifedipine/NN ,/, Vardenafil/NN 20/CD mg/NN produced/VBD mean/JJ additional/JJ supine/NN systolic/diastolic/JJ blood/NN pressure/NN reductions/NNS of/IN 6/5/CD mm/NN Hg/NN compared/VBN to/TO placebo/NN ./.


DrugDDI.d253
DrugDDI.d253.s28
Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin , significant hypotension developed in a substantial number of subjects.

Alpha-blockers/NNS :/: When/WRB Vardenafil/NN 10/CD or/CC 20/CD mg/NN was/VBD given/VBN to/TO healthy/JJ volunteers/NNS either/CC simultaneously/RB or/CC 6/CD hours/NNS after/IN a/DT 10/CD mg/NN dose/NN of/IN terazosin/NN ,/, significant/JJ hypotension/NN developed/VBD in/IN a/DT substantial/JJ number/NN of/IN subjects/NNS ./.


DrugDDI.d253
DrugDDI.d253.s29
With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.

With/IN simultaneous/JJ dosing/NN of/IN Vardenafil/NN 10/CD mg/NN and/CC terazosin/NN 10/CD mg/NN ,/, 6/CD of/IN 8/CD subjects/NNS experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN of/IN less/JJR than/IN 85/CD mm/NN Hg/NN ./.


DrugDDI.d253
DrugDDI.d253.s30
With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.

With/IN simultaneous/JJ dosing/NN of/IN Vardenafil/NN 20/CD mg/NN and/CC terazosin/NN 10/CD mg/NN ,/, 2/CD of/IN 9/CD subjects/NNS experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN of/IN less/JJR than/IN 85/CD mm/NN Hg/NN ./.


DrugDDI.d253
DrugDDI.d253.s31
When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.

When/WRB Vardenafil/NN dosing/NN was/VBD separated/VBN from/IN terazosin/NN 10/CD mg/NN by/IN 6/CD hours/NNS ,/, 7/CD of/IN 28/CD subjects/NNS who/WP received/VBD 20/CD mg/NN of/IN Vardenafil/NN experienced/VBN a/DT decrease/NN in/IN standing/JJ systolic/JJ blood/NN pressure/NN below/IN 85/CD mm/NN Hg/NN ./.


DrugDDI.d253
DrugDDI.d253.s32
In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.

In/IN a/DT similar/JJ study/NN with/IN tamsulosin/NN in/IN healthy/JJ volunteers/NNS ,/, 1/CD of/IN 24/CD subjects/NNS dosed/VBN with/IN Vardenafil/NN 20/CD mg/NN and/CC tamsulosin/NN 0.4/CD mg/NN separated/VBN by/IN 6/CD hours/NNS experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN below/IN 85/CD mm/NN Hg/NN ./.


DrugDDI.d253
DrugDDI.d253.s33
Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.

Two/CD of/IN 16/CD subjects/NNS dosed/VBN simultaneously/RB with/IN Vardenafil/NN 10/CD mg/NN and/CC tamsulosin/NN 0.4/CD mg/NN experienced/VBN a/DT standing/JJ systolic/JJ blood/NN pressure/NN below/IN 85/CD mm/NN Hg/NN ./.


DrugDDI.d253
DrugDDI.d253.s34
The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.

The/DT administration/NN of/IN lower/JJR doses/NNS of/IN Vardenafil/NN with/IN alpha-blockers/NNS has/VBZ not/RB been/VBN completely/RB evaluated/VBN to/TO determine/VB if/IN they/PRP can/MD be/VB safely/RB administered/VBN together/RB ./.


DrugDDI.d253
DrugDDI.d253.s35
Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.

Based/VBN on/IN these/DT data/NNS ,/, Vardenafil/NN should/MD not/RB be/VB used/VBN in/IN patients/NNS on/IN alpha-blocker/NN therapy/NN ./.


DrugDDI.d253
DrugDDI.d253.s36
Ritonavir and indinavir : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir , the Cmax and AUC of ritonavir were reduced by approximately 20%.

Ritonavir/NN and/CC indinavir/NN :/: Upon/IN concomitant/JJ administration/NN of/IN 5/CD mg/NN of/IN Vardenafil/NN with/IN 600/CD mg/NN BID/NN ritonavir/NN ,/, the/DT Cmax/NN and/CC AUC/NN of/IN ritonavir/NN were/VBD reduced/VBN by/IN approximately/RB 20/CD %./NN


DrugDDI.d253
DrugDDI.d253.s37
Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir , the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.

Upon/IN administration/NN of/IN 10/CD mg/NN of/IN Vardenafil/NN with/IN 800/CD mg/NN TID/NN indinavir/NN ,/, the/DT Cmax/NN and/CC AUC/NN of/IN indinavir/NN were/VBD reduced/VBN by/IN 40/CD %/NN and/CC 30/CD %/NN ,/, respectively/RB ./.


DrugDDI.d253
DrugDDI.d253.s38
Alcohol : Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.

Alcohol/NN :/: Alcohol/NN (/-LRB- 0.5/CD g/kg/NN body/NN weight/NN :/: approximately/RB 40/CD mL/NN of/IN absolute/JJ alcohol/NN in/IN a/DT 70/CD kg/NN person/NN )/-RRB- and/CC vardenafil/NN plasma/NN levels/NNS were/VBD not/RB altered/VBN when/WRB dosed/VBN simultaneously/RB ./.


DrugDDI.d253
DrugDDI.d253.s39
Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).

Vardenafil/NN (/-LRB- 20/CD mg/NN )/-RRB- did/VBD not/RB potentiate/VB the/DT hypotensive/JJ effects/NNS of/IN alcohol/NN during/IN the/DT 4-hour/JJ observation/NN period/NN in/IN healthy/JJ volunteers/NNS when/WRB administered/VBN with/IN alcohol/NN (/-LRB- 0.5/CD g/kg/NN body/NN weight/NN )./CD


DrugDDI.d253
DrugDDI.d253.s40
Aspirin : Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).

Aspirin/NN :/: Vardenafil/NN (/-LRB- 10/CD mg/NN and/CC 20/CD mg/NN )/-RRB- did/VBD not/RB potentiate/VB the/DT increase/NN in/IN bleeding/JJ time/NN caused/VBN by/IN aspirin/NN (/-LRB- two/CD 81/CD mg/NN tablets/NNS )./CD


DrugDDI.d253
DrugDDI.d253.s41
Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide ( glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).

Other/JJ interactions/NNS :/: Vardenafil/NN had/VBD no/DT effect/NN on/IN the/DT pharmacodynamics/NNS of/IN glyburide/NN (/-LRB- glucose/NN and/CC insulin/NN concentrations/NNS )/-RRB- and/CC warfarin/NN (/-LRB- prothrombin/NN time/NN or/CC other/JJ pharmacodynamic/JJ parameters/NNS )./NN


DrugDDI.d528
DrugDDI.d528.s0
Zidovudine : There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.

Zidovudine/NN :/: There/EX is/VBZ no/DT significant/JJ pharmacokinetic/JJ interaction/NN between/IN ZDV/NN and/CC zalcitabine/NN which/WDT has/VBZ been/VBN confirmed/VBN clinically/RB ./.


DrugDDI.d528
DrugDDI.d528.s1
Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV , as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).

Zalcitabine/NN also/RB has/VBZ no/DT significant/JJ effect/NN on/IN the/DT intracellular/JJ phosphorylation/NN of/IN ZDV/NN ,/, as/IN shown/VBN in/FW vitro/FW in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS or/CC in/IN two/CD other/JJ cell/NN lines/NNS (/-LRB- U937/NN and/CC Molt-4/NN )./NN


DrugDDI.d528
DrugDDI.d528.s2
In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.

In/IN the/DT same/JJ study/NN it/PRP was/VBD shown/VBN that/IN didanosine/NN and/CC stavudine/NN had/VBD no/DT significant/JJ effect/NN on/IN the/DT intracellular/JJ phosphorylation/NN of/IN zalcitabine/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./.


DrugDDI.d528
DrugDDI.d528.s3
Lamivudine : In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.

Lamivudine/NN :/: In/FW vitro/FW studies/NNS in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ,/, U937/NN and/CC Molt-4/NN cells/NNS revealed/VBD that/IN lamivudine/NN significantly/RB inhibited/VBD zalcitabine/NN phosphorylation/NN in/IN a/DT dose/NN dependent/JJ manner/NN ./.


DrugDDI.d528
DrugDDI.d528.s4
Effects were already seen with doses corresponding to relevant plasma levels in humans, and the intracellular phosphorylation of zalcitabine to its three metabolites (including the active zalcitabine triphosphate metabolite) was significantly inhibited.

Effects/NNS were/VBD already/RB seen/VBN with/IN doses/NNS corresponding/VBG to/TO relevant/JJ plasma/NN levels/NNS in/IN humans/NNS ,/, and/CC the/DT intracellular/JJ phosphorylation/NN of/IN zalcitabine/NN to/TO its/PRP$ three/CD metabolites/NNS (/-LRB- including/VBG the/DT active/JJ zalcitabine/NN triphosphate/NN metabolite/NN )/-RRB- was/VBD significantly/RB inhibited/VBN ./.


DrugDDI.d528
DrugDDI.d528.s5
Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100); .

Zalcitabine/NN inhibited/VBD lamivudine/NN phosphorylation/NN at/IN high/JJ concentration/NN ratios/NNS (/-LRB- 10/CD and/CC 100/CD )/-RRB- ;/: ./.


DrugDDI.d528
DrugDDI.d528.s6
however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine .

however/RB ,/, it/PRP is/VBZ considered/VBN to/TO be/VB unlikely/JJ that/IN this/DT decrease/NN of/IN phosphorylated/VBN lamivudine/NN concentration/NN is/VBZ of/IN clinical/JJ significance/NN ,/, as/IN lamivudine/NN is/VBZ a/DT more/RBR efficient/JJ substrate/NN for/IN deoxycytidine/NN kinase/NN than/IN zalcitabine/NN ./.


DrugDDI.d528
DrugDDI.d528.s7
These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine , which may lead to a decreased antiretroviral effect of zalcitabine .

These/DT in/FW vitro/FW studies/NNS suggest/VBP that/IN concomitant/JJ administration/NN of/IN zalcitabine/NN and/CC lamivudine/NN in/IN humans/NNS may/MD result/VB in/IN sub-therapeutic/JJ concentrations/NNS of/IN active/JJ phosphorylated/JJ zalcitabine/NN ,/, which/WDT may/MD lead/VB to/TO a/DT decreased/VBN antiretroviral/JJ effect/NN of/IN zalcitabine/NN ./.


DrugDDI.d528
DrugDDI.d528.s9
Concomitant use of zalcitabine and lamivudine is not recommended.

Concomitant/JJ use/NN of/IN zalcitabine/NN and/CC lamivudine/NN is/VBZ not/RB recommended/VBN ./.


DrugDDI.d528
DrugDDI.d528.s10
Saquinavir : The combination of HIVID , saquinavir , and ZDV has been studied (as triple combination) in adults.

Saquinavir/NN :/: The/DT combination/NN of/IN HIVID/NN ,/, saquinavir/NN ,/, and/CC ZDV/NN has/VBZ been/VBN studied/VBN (/-LRB- as/IN triple/JJ combination/NN )/-RRB- in/IN adults/NNS ./.


DrugDDI.d528
DrugDDI.d528.s11
Pharmacokinetic data suggest that absorption, metabolism, and elimination of each of these drugs are unchanged when they are used together.

Pharmacokinetic/JJ data/NNS suggest/VBP that/IN absorption/NN ,/, metabolism/NN ,/, and/CC elimination/NN of/IN each/DT of/IN these/DT drugs/NNS are/VBP unchanged/JJ when/WRB they/PRP are/VBP used/VBN together/RB ./.


DrugDDI.d528
DrugDDI.d528.s12
Drugs Associated With Peripheral Neuropathy: The concomitant use of HIVID with drugs that have the potential to cause peripheral neuropathy should be avoided where possible.

Drugs/NNS Associated/VBN With/IN Peripheral/JJ Neuropathy/NN :/: The/DT concomitant/JJ use/NN of/IN HIVID/NN with/IN drugs/NNS that/WDT have/VBP the/DT potential/NN to/TO cause/VB peripheral/JJ neuropathy/NN should/MD be/VB avoided/VBN where/WRB possible/JJ ./.


DrugDDI.d528
DrugDDI.d528.s13
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .

Drugs/NNS that/WDT have/VBP been/VBN associated/VBN with/IN peripheral/JJ neuropathy/NN include/VBP antiretroviral/JJ nucleoside/NN analogues/NNS ,/, chloramphenicol/NN ,/, cisplatin/NN ,/, dapsone/NN ,/, disulfiram/NN ,/, ethionamide/NN ,/, glutethimide/NN ,/, gold/NN ,/, hydralazine/NN ,/, iodoquinol/NN ,/, isoniazid/NN ,/, metronidazole/NN ,/, nitrofurantoin/NN ,/, phenytoin/NN ,/, ribavirin/NN ,/, and/CC vincristine/NN ./.


DrugDDI.d528
DrugDDI.d528.s14
Concomitant use of HIVID with didanosine is not recommended.

Concomitant/JJ use/NN of/IN HIVID/NN with/IN didanosine/NN is/VBZ not/RB recommended/VBN ./.


DrugDDI.d528
DrugDDI.d528.s15
Intravenous Pentamidin e: Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.

Intravenous/JJ Pentamidin/NN e/NN :/: Treatment/NN with/IN HIVID/NN should/MD be/VB interrupted/VBN when/WRB the/DT use/NN of/IN a/DT drug/NN that/WDT has/VBZ the/DT potential/NN to/TO cause/VB pancreatitis/NN is/VBZ required/VBN ./.


DrugDDI.d528
DrugDDI.d528.s16
Death due to fulminant pancreatitis possibly related to intravenous pentamidin e and HIVID has been reported.

Death/NN due/IN to/TO fulminant/JJ pancreatitis/NN possibly/RB related/JJ to/TO intravenous/JJ pentamidin/NN e/NN and/CC HIVID/NN has/VBZ been/VBN reported/VBN ./.


DrugDDI.d528
DrugDDI.d528.s17
If intravenous pentamidin e is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.

If/IN intravenous/JJ pentamidin/NN e/NN is/VBZ required/VBN to/TO treat/VB Pneumocystis/NN carinii/NN pneumonia/NNS ,/, treatment/NN with/IN HIVID/NN should/MD be/VB interrupted/VBN ./.


DrugDDI.d528
DrugDDI.d528.s18
Amphotericin , Foscarnet , and Aminoglycosides : Drugs such as amphotericin , foscarnet , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).

Amphotericin/NN ,/, Foscarnet/NN ,/, and/CC Aminoglycosides/NN :/: Drugs/NNS such/JJ as/IN amphotericin/NN ,/, foscarnet/NN ,/, and/CC aminoglycosides/NNS may/MD increase/VB the/DT risk/NN of/IN developing/VBG peripheral/JJ neuropathy/NN or/CC other/JJ HIVID/NN -associated/JJ adverse/JJ events/NNS by/IN interfering/VBG with/IN the/DT renal/JJ clearance/NN of/IN zalcitabine/NN (/-LRB- thereby/RB raising/VBG systemic/JJ exposure/NN )./NN


DrugDDI.d528
DrugDDI.d528.s19
Patients who require the use of one of these drugs with HIVID should have frequent clinical and laboratory monitoring with dosage adjustment for any significant change in renal function.

Patients/NNS who/WP require/VBP the/DT use/NN of/IN one/CD of/IN these/DT drugs/NNS with/IN HIVID/NN should/MD have/VBP frequent/JJ clinical/JJ and/CC laboratory/JJ monitoring/NN with/IN dosage/JJ adjustment/NN for/IN any/DT significant/JJ change/NN in/IN renal/JJ function/NN ./.


DrugDDI.d528
DrugDDI.d528.s20
Probenecid or Cimetidine : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine , most likely by inhibition of renal tubular secretion of zalcitabine .

Probenecid/NN or/CC Cimetidine/NN :/: Concomitant/JJ administration/NN of/IN probenecid/NN or/CC cimetidine/NN decreases/VBZ the/DT elimination/NN of/IN zalcitabine/NN ,/, most/RBS likely/RB by/IN inhibition/NN of/IN renal/JJ tubular/JJ secretion/NN of/IN zalcitabine/NN ./.


DrugDDI.d528
DrugDDI.d528.s21
Patients receiving these drugs in combination with zalcitabine should be monitored for signs of toxicity and the dose of zalcitabine reduced if warranted.

Patients/NNS receiving/VBG these/DT drugs/NNS in/IN combination/NN with/IN zalcitabine/NN should/MD be/VB monitored/VBN for/IN signs/NNS of/IN toxicity/NN and/CC the/DT dose/NN of/IN zalcitabine/NN reduced/VBD if/IN warranted/VBN ./.


DrugDDI.d528
DrugDDI.d528.s22
Magnesium /Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium /aluminum-containing antacid products.

Magnesium/NN /Aluminum-containing/JJ Antacid/JJ Products/NNS :/: Absorption/NN of/IN zalcitabine/NN is/VBZ moderately/RB reduced/VBN (/-LRB- approximately/RB 25/CD %/NN )/-RRB- when/WRB coadministered/VBN with/IN magnesium/NN /aluminum-containing/NN antacid/JJ products/NNS ./.


DrugDDI.d528
DrugDDI.d528.s23
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium / aluminum-containing antacids .

The/DT clinical/JJ significance/NN of/IN this/DT reduction/NN is/VBZ not/RB known/VBN ,/, hence/RB zalcitabine/NN is/VBZ not/RB recommended/VBN to/TO be/VB ingested/VBN simultaneously/RB with/IN magnesium/NN //: aluminum-containing/JJ antacids/NNS ./.


DrugDDI.d528
DrugDDI.d528.s24
Metoclopramide : Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.

Metoclopramide/NN :/: Bioavailability/NN is/VBZ mildly/RB reduced/VBN (/-LRB- approximately/RB 10/CD %/NN )/-RRB- when/WRB zalcitabine/NN and/CC metoclopramide/NN are/VBP coadministered/VBN ./.


DrugDDI.d528
DrugDDI.d528.s25
Doxorubicin : Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.

Doxorubicin/NN :/: Doxorubicin/NN caused/VBD a/DT decrease/NN in/IN zalcitabine/NN phosphorylation/NN (/-LRB- 50/CD %/NN inhibition/NN of/IN total/JJ phosphate/NN formation/NN )/-RRB- in/IN U937/Molt/NN 4/CD cells/NNS ./.


DrugDDI.d528
DrugDDI.d528.s26
Although there may be decreased zalcitabine activity because of lessened active metabolite formation, the clinical relevance of these in vitro results are not known.

Although/IN there/EX may/MD be/VB decreased/VBN zalcitabine/NN activity/NN because/IN of/IN lessened/JJ active/JJ metabolite/NN formation/NN ,/, the/DT clinical/JJ relevance/NN of/IN these/DT in/FW vitro/FW results/NNS are/VBP not/RB known/VBN ./.


